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ABSTRACT 
 
 Despite many therapeutic advances, the rate of heart failure after myocardial 
infarction remains very high. Therefore, there is still significant need to develop better 
therapeutics to treat heart failure. One potential mark is the protein, mechanistic target 
of rapamycin (mTOR), a key signaling kinase for most cell types. Overexpression of 
mTOR has been previously shown by our lab as sufficient to protect the heart against 
different stressors including ischemia-reperfusion (I/R) injury, TAC-induced hypertrophy, 
and metabolic syndrome and obesity. As our laboratory is most concerned with the role 
of mTOR in I/R injury, in this dissertation I wanted to determine if mTOR was necessary 
for cardioprotection in I/R against various pathological settings, including diabetes 
mellitus (DM).  
 To do this, I generated a tamoxifen-inducible, cardiac muscle specific mTOR 
knockout (CKO) mouse model to evaluate the loss of mTOR in functional studies, 
especially I/R injury. I initially characterized heart physiology in the CKO mouse at 
baseline using echocardiography. Preliminary in vivo I/R injury and ex vivo Langendorff 
I/R using acute inhibition of mTOR by Torin1 administration suggested mTOR was 
necessary to protect the heart as the recovery of the CKO group was significantly worse 
than that of littermate controls in both settings. However, when CKO hearts were 
subjected to I/R using the ex vivo system, CKO hearts surprisingly exhibited had better 
cardiac function following I/R than control hearts. This was also the case in a mouse 
model of obesity and hyperglycemia. CKO hearts also had irregular contractility, a 
finding that led to the investigation of Ca2+ handling in these CKO mice. Cardiomyocytes 
(CM) isolated from CKO mice displayed weaker contractions and smaller calcium (Ca2+) 
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transients as well as a reduction in relative SR Ca2+ content. Insulin also blunted the 
recovery of these mice, showing mTOR is at least partially necessary for 
cardioprotection against I/R injury. The findings in this study may be caused by 
decreased expression of the IP3R, which plays an important role in regulating Ca2+ 
transfer from the ER to the mitochondria, since that was found to be lower in the 
SR/mitochondria fraction of CKO hearts. However, a clear mechanism for explaining 
these results still needs to be identified. A novel role for mTOR in Ca2+ handling and 
contraction could bring new insights into potential therapeutics for treating and 
managing heart failure.  
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Chapter One 
 
 
INTRODUCTION 
  
 
1.1 Introduction 
Myocardial infarction (MI) and later heart failure (HF) continue to be among the 
leading causes of morbidity and mortality for patients in the United States. Despite 
therapeutic advances such as coronary stents and bypass surgery, HF prevalence in 
the United States has actually increased from 5.7 million people to 6.5 million from 2009 
to 2014 although the five-year survival rate improved [1]. Therefore, there is still 
significant need to discover potential therapeutic targets in order to prevent and treat HF 
and cardiovascular disease (CVD) in general.  
 The mechanistic target of rapamycin (mTOR) kinase plays a key role in the 
insulin-signaling pathway and is known to protect the heart against ischemia/reperfusion 
(I/R) injury [2-4]. However, the mechanism behind the cardioprotective effects of 
mTOR in I/R injury remains unknown. A recent study suggested mTOR may be 
localized between the sarcoplasmic reticulum (SR) and the mitochondria and may have 
a role in regulating calcium (Ca2+) transients [5]. Intracellular Ca2+ plays a central role in 
Excitation-Contraction (EC) Coupling for muscle contraction and in cell death by Ca2+ 
overload through the mitochondrial permeability transition pore (mPTP) [6]. A role for 
mTOR in Ca2+ transients may explain the cardioprotective effects of mTOR in I/R injury.  
 To further investigate the role of mTOR in cardioprotection, I generated 
cardiomyocyte (CM) specific, tamoxifen-inducible Cre mTOR knockout (CKO) mice and 
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assessed the cardiac function of their hearts using ex vivo Langendorff to generate 
global ischemia, and in vitro using IonOptix. IonOptix is specialized software that uses a 
dual excitation photometer system and an edge detector to evaluate contraction and 
Ca2+ transients. Preliminary data showed that the CKO mice displayed significantly 
worse recovery after in vivo I/R injury. Our previous studies using our mice with cardiac 
specific mTOR overexpressing transgene (mTOR-Tg) demonstrated mTOR was 
cardioprotective in a variety of pathologies. mTOR overexpression resulted in improved 
cardiac function post I/R injury, after transverse aortic constriction (TAC) induced 
hypertrophy, and in a mouse model of obesity [2, 7, 8]. These studies all suggested 
mTOR was sufficient to protect the heart against these certain stressors. A previous 
report using cardiac-specific mTOR knockout mice showed that deletion of cardiac 
mTOR accelerates heart failure progression in TAC-induced hypertrophy [9]. However, 
a mechanism of how mTOR regulates cardioprotective effects in I/R injury remains 
undefined. Therefore, my overall hypothesis is that mTOR is necessary to protect the 
heart against I/R in various pathological settings including diabetes mellitus (DM). To 
test this hypothesis, I performed experiments addressing the following three specific 
aims that will be addressed in the specified chapters:   
 
Specific Aim 1 (Chapter Two): To determine the necessity of mTOR in I/R injury 
by using the ex vivo Langendorff method.  
 For this aim, I investigated the effects of loss of mTOR by generating and 
validating a CM specific, tamoxifen-inducible Cre mTOR knockdown (CKO) line. I 
evaluated the CKO mice versus their littermate controls (CON) at baseline and after ex 
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vivo I/R injury to determine whether mTOR was necessary to protect CMs from cell 
death.  
 
Specific Aim 2 (Chapter Three): To define the role of mTOR in cardiomyocyte Ca2+ 
signaling and EC-coupling. 
 By isolating CMs from adult mTOR-CKO mice, I was able to measure how 
contractility and Ca2+ transients were affected by the loss of mTOR. Sarcomere length 
(SL) shortening and intracellular Ca2+ transients were assessed as indicators of cardiac 
function using the IonOptix technology. To determine if release or reuptake was affected 
in mTOR-CKO CMs, I analyzed Ca2+ upon stimulation with isoproterenol and caffeine.   
 
Specific Aim 3 (Chapter Four): To define the role of mTOR in ischemia-
reperfusion injury in a mouse model of diabetes mellitus (DM).  
 For this section, I measured the cardiac function of our CKO and CON mice in a 
mouse model of obesity. I placed the CKO and CON mice on a high fat diet (HFD) for 
12 weeks beginning at 6-8 weeks of age. At the end of the 12 weeks, the mice were 
weighed and fasting blood glucose was measured. I subjected hearts from CON and 
CKO mice to I/R injury using the ex vivo Langendorff system. I also evaluated the 
effects of insulin on the CKO and CON mice using the ex vivo system.   
1.2 Myocardial infarction, cardiac remodeling, and the development of 
subsequent heart failure 
Myocardial infarction and subsequent heart failure still remains a significant cause 
of mortality in the United States with an estimated 5 million Americans diagnosed with 
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congestive heart failure (CHF). Epidemiological reports estimate the rate of heart failure 
after MI to be around 25% [10]. The post-MI development of heart failure depends on 
multiple factors including size of infarct, location, and time to reperfusion or 
revascularization.  
 Cardiac remodeling is the underlying molecular mechanism by which heart failure 
occurs after an MI and is also influenced by many factors such as hemodynamic load, 
neurohormonal activation, cytokines such as tumor necrosis factor (TNF) and nitric 
oxide (NO), and oxidative stress [11]. The process of left ventricular (LV) remodeling 
begins rapidly, usually within the first few hours after an infarct and continues to 
progress over time due to a variety of cellular changes involving many different 
components and factors [12, 13]. The major contributors to cardiac remodeling are 
cardiac myocyte cell death, fibroblast proliferation, and collagen deposition [14-17]. 
Previous clinical studies strongly suggest that the magnitude of LV remodeling in 
patients is directly proportional to the initial infarct size following acute MI, including 
reperfusion injury [18, 19]. Thus, the CM cell death is perhaps one of the most important 
components in LV remodeling. After an MI, CMs die and cause the surviving myocytes 
to become elongated or hypertrophied as a compensatory mechanism. This in turn 
leads to increased ventricular wall thickness, altered loading conditions, and wall stress. 
These changes result in energy imbalance and further ischemia and feeding a vicious 
cycle of continual ventricular remodeling [20]. 
 Eventually, all of these changes lead to a progressive worsening of cardiac 
function and heart failure. Generally, patients with a greater extent of remodeling have a 
poorer prognosis and outcome than those that do not, especially those with a reduced 
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LV ejection fraction [21]. This is especially true in the post-MI population where LV end-
systolic volume (LVESV) is the strongest prognostic indicator. Those with the lowest 
LVESV are correlated with the patients having the highest morbidity [22].    
 
1.3 Background and signaling pathway of mTOR  
The mechanistic target of rapamycin (mTOR) was originally discovered through a 
genetic screen in budding yeasts as a target of the drug rapamycin in 1993 [23, 24]. 
Shortly thereafter, mTOR was purified and characterized in mammalian cells by three 
independent studies [25-27]. Following these pioneer studies, mTOR has been found to 
be a very important cell regulator with multiple different functions. It is a large (289 kDa), 
atypical serine/threonine kinase, and belongs to the phosphatidylinositol kinase-related 
family (PIKK) [28]. Structural studies revealed that it contains several tandem HEAT 
repeats, a central focal adhesion targeting (FAT) domain, a FRB domain, a catalytic 
kinase domain and the c-terminal FAT (FATC) domain [29] (Figure 1.1).  
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Figure 1.1. The structure of mTOR. 
Crystallography structure of a N-terminally truncated mTOR showing its FAT, FRB, kinase, and 
FATC domains. Yang, et. al 2013.  
 
mTOR forms two multi-protein complexes, mTORC1 and mTORC2 [4, 30]. 
mTORC1 is the rapamycin sensitive complex and is activated by amino acids, 
especially leucine, and by stress, oxygen, energy, and growth factors [4, 30, 31]. 
mTORC1 binding proteins consist of regulatory associated protein of mTOR (RAPTOR), 
mammalian lethal with Sec13 protein (mLST8), proline-rich Akt/PKB substrate 40 kDa 
(PRAS40), and DEP-domain-containing mTOR interacting protein (DEPTOR) [32-35]. 
mTORC1 is downstream of Akt and activates the p70S6 kinase (p70S6K) and 4E-
binding protein1 (4E-BP1). Central to many signaling pathways, mTORC1 regulates 
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aspects of protein synthesis, cell growth, proliferation, ribosomal and mitochondrial 
biogenesis, autophagy, and metabolism.  
mTORC2 is the rapamycin insensitive complex and is upstream of Akt. mTORC2 
activates Akt by phosphorylating Akt at its Ser473 site. Its binding partners consist of 
rapamycin-insensitive companion of mTOR (RICTOR), mammalian stress-activated 
protein kinase [SAPK]-interacting protein (mSin1), protein observed with rictor-1 
(PROTOR), DEPTOR, and mLST8 [36-38]. mTORC2 has been shown to regulate cell 
survival and actin organization [4, 30, 39-42] (Figure 1.2 and 1.3). 
 
 
Figure 1.2. mTOR complexes 1 and 2 and their associated proteins.  
mTORC1 is associated with raptor, mLST8, DEPTOR, and PRAS40. mTORC2 is associated 
with rictor, mLST, DEPTOR, PROTOR, and SIN1.  	  
 
Originally mTOR was found to be a downstream target of the insulin-signaling 
pathway. However, it can also be activated by amino acids, especially leucine and 
arginine, through the activation of Rag GTPases associated with ras homolog enriched 
in brain (Rheb) [43-45]. The binding of insulin to its receptor causes the receptor to 
undergo a conformational change activating the tyrosine kinase activity on the 
intracellular side of the receptor. This promotes the recruitment of insulin receptor 
substrate 1 (IRS1), leading to activation of phosphoinositide 3-kinase (PI3K) and the 
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production of phosphatidylinositol (3,4,5)-triphosphate (PIP3). This in turn recruits and 
activates Akt at the plasma membrane [46].  Akt activation by growth factors can also 
activate mTORC1 in a tuber sclerosis complex 1 and 2 (TSC1/2) independent manner 
by promoting the phosphorylation and dissociation of PRAS from mTORC1 [34, 47]. Akt 
regulates mTORC1 activity via the tuberous sclerosis complex 1 and 2 (TSC-1/2) and 
Rheb [48, 49]. Akt inhibits TSC2 by phosphorylating it, thereby activating Rheb. This in 
turn activates mTORC1. mTORC1 phosphorylates p70S6K activating ribosomal protein 
S6 (S6). mTORC1 also inactivates 4E-BPs, thereby activating the eukaryotic translation 
initiation factor 4E (elF4E) and promoting translation (Figure 1.3).  
On the other hand, less is known about mTORC2 regulation and signaling 
although it is known that mTORC2 can control survival by phosphorylating several 
members of the AGC (PKA/PKG/PKC) family of protein kinases [50-52]. However, the 
most important and primary role of mTORC2 is to directly phosphorylate Akt on its 
Ser473 site, with this phosphorylation event, and with phosphoinositide-dependent 
kinase 1 (PDK1), phosphorylating the Thr308 site, Akt becomes activated [53]. Akt is an 
extremely important cell regulator responsible for controlling cell survival, proliferation, 
and growth (Figure 1.3).    
	  9	  
 
 
Figure 1.3. The mTOR-signaling pathway 
mTOR is a central subunit in two complexes, mTORC1 and mTORC2. mTORC1 is the 
rapamycin sensitive complex and is activated by insulin, IGF-1 and other growth factors by an 
Akt dependent mechanism. mTORC1 activates p70S6k which forms a negative feedback loop 
on IRS-1. mTORC2 is the rapamycin insensitive complex and activates Akt on its serine473 
site. Tel2/Tti1 stabilize both complexes. mTORC1 is involved in protein synthesis, proliferation 
and autophagy whereas mTORC2 is involved in cell survival and actin organization.  
 
 
1.4 The role of mTOR in cardiac function and cell survival 
Physiological and pathophysiological roles of mTOR in the heart is complicated 
due to the dual complexes mTOR forms. Several studies using mouse models of 
pathological cardiac hypertrophy reported that treating with rapamycin and its 
derivatives (e.g. sirolimus and everolimus) inhibited cardiac hypertrophy and preserved 
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cardiac function [54, 55]. Other groups showed pretreatment with rapamycin also 
protects the heart against I/R injury in an ex vivo Langendorff model. Mice treated with 
rapamycin had lower infarct sizes, improved cardiac function, and had significantly 
lower rates of both necrosis and apoptosis [56, 57]. Another group confirmed this finding 
using a model of in vivo I/R injury and found everolimus (a rapamycin derivative) to 
once again be beneficial by applying the drug on the day or three days after the I/R 
surgery [58]. 
However, in contrast to these findings, our group reported a protective effect of 
mTOR in I/R injury. Using cardiac-specific transgenic mice overexpressing wild-type 
mTOR driven by an α-myosin heavy chain (αMHC) promoter (mTOR-Tg), we subjected 
these mice to both in vivo and ex vivo I/R injury. Both models of I/R demonstrated 
improved cardiac function compared to littermate controls after I/R injury as well as 
decreased CM cell death as indicated by the amount of creatine kinase (CK) released 
into the perfusate post I/R. Masson’s trichrome staining showed that 28 days after in 
vivo I/R, mTOR-Tg mice had a significantly smaller area of interstitial fibrosis compared 
to wild-type (WT) mice. Consistent with this finding, mTOR-Tg hearts subjected to ex 
vivo I/R had less necrosis as indicated by Evans blue dye staining [2]. Other groups 
have also shown that insulin-mediated protection against CM cell death is largely 
dependent on the activation of PI3K, Akt, and mTOR; again indicating mTOR activation 
is beneficial for cardioprotection [59, 60]. Further supporting mTOR as cardioprotective 
is our preliminary data using a tamoxifen inducible, cardiac specific mTOR knockout 
(CKO) mouse. We subjected these mice and their littermate controls to in vivo I/R injury 
by left anterior descending coronary artery (LAD) ligation and found that the CKO mice 
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had significantly worse cardiac function and substantially more fibrosis just seven days 
after the surgery (Figure 1.4). 
 
Figure 1.4. mTOR-KO have significantly increased fibrosis and decreased % fractional 
shortening (%FS) 7 days after in vivo I/R injury.  
Top. Representative Masson’s trichrome staining showing a significantly larger area of fibrosis 
in CKO hearts compared to controls. Bottom. Quantification of %FS using echocardiography 
showing CKO hearts have significantly decreased %FS compared to controls. N= 6 (CON) and 
7 (CKO). p-values displayed on graph.  
 
These opposing findings may be explained by a negative feedback loop where 
mTORC1 signaling through S6K1 negatively regulates Akt by inhibiting insulin receptor 
substrate-1 (IRS-1) [61, 62]. Several groups have demonstrated rapamycin inhibits this 
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negative feedback loop leading to the activation of Akt via mTORC2 and suppresses 
apoptosis in post-MI hearts and other pathological stimuli [56, 63, 64]. On the other 
hand, overexpression of mTOR increased the phosphorylation of both S6 and Akt 
following I/R injury [2]. Increased phosphorylation of S6 and Akt indicates mTORC1 and 
mTORC2 signaling are increased in mTOR-Tg mice. Therefore, the signaling pathways 
that lead to cardiac protection by rapamycin and the genetic mTOR-Tg mice are 
different and may explain the contradictory findings. 
 
1.5 Regulation of cardiac muscle contraction and calcium transients 
physiological and heart failure settings  
 Ca2+ is the key element for controlling and regulating cardiac muscle contraction 
[65]. In normal conditions, during the cardiac action potential, the myocyte membrane 
depolarizes leading extracellular Ca2+ to enter the cell through the L-type voltage 
dependent Ca2+ channel. This inward Ca2+ current is insufficient to cause contraction by 
itself [66]. However, this initial inward movement of Ca2+ acts as an amplification signal 
for the release of Ca2+ from the SR and triggers Ca2+-induced Ca2+ release (CICR) from 
adjacent type 2 ryanodine receptors (RyR2s) on the SR membrane [67]. RyR activity is 
closely tied to cytosolic Ca2+ levels with low concentrations (1-10 µM) being activatory 
while high concentrations (> 10 µM) are inhibitory [68]. Activation of the RyRs and Ca2+ 
release from the SR produces a Ca2+ release signal known as a “Ca2+ spark” [69]. 
Multiple Ca2+ sparks produces enough intracellular Ca2+ in order to trigger contraction 
(Figure 1.5). 
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Figure 1.5. EC-Coupling under normal physiological conditions.  
Under normal physiological conditions, Ca2+ enters the cell through L-type Ca2+ channels 
triggering Ca2+ induced Ca2+ release from the SR and contraction. Following contraction, Ca2+ 
returns to the SR by SERCA or is effluxed out of the cell through the NCX-1.  
 
Contraction is triggered when the Ca2+ released from the SR travels to the 
adjacent myofibrils where it binds to troponin C on the troponin-tropomyosin complex 
[70]. Myofilaments consist of an array of thick and thin filaments [71]. The sarcomere is 
composed of one unit of interacting thin and thick filaments. Thick filaments are 
composed of myosin heavy chains and two pairs of light chains. Ca2+ binding causes 
tropomyosin to move away from binding sites allows the formation of cross-bridges 
between actin and myosin [72]. This facilitates the “power-stroke” causing the myocyte 
to contract [73]. Following contraction, the Ca2+ is then returned to the SR by the 
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) or is effluxed out of the cell via the 
Na+/Ca2+ exchanger (NCX-1) [74]. A small amount of Ca2+ also goes into the 
mitochondria.  
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 In heart failure, reduced SR Ca2+ and Ca2+ release is the central cause of 
contractile dysfunction and arrhythmias [75]. This results in the generation of a smaller 
contractile force. There are multiple factors that can lower SR Ca2+ in heart failure 
although a major cause is the down-regulation of the SERCA pump [76]. Reduced SR 
Ca2+ uptake can also be attributed to the decreased activity of phospholamban (PLN) 
[77-80]. Dephosphorylated PLN inhibits SERCA, and some studies have shown that 
phosphorylation of PLN is decreased in the failing human heart [77, 79]. Another 
potential cause is the up-regulation of NCX resulting in more Ca2+ being removed from 
the cell [81]. Increased phosphorylation of RYRs also causes further depletion of Ca2+ 
stores due to diastolic leak of SR Ca2+ through RYR2 channels [82]. Additionally, 
diastolic leak of SR Ca2+ is also the primary mechanism resulting in delayed 
afterdepolarizations, triggered ventricular arrhythmias and sudden death in heart failure, 
though NCX upregulation is also a contributing factor [83-85] (Figure 1.6). Overall, these 
changes in proteins typically involved with EC-coupling result in reduced SR Ca2+ load 
and smaller Ca2+ transients [86]. All of these factors contribute to the contractile 
dysfunction typically seen in heart failure.  
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Figure 1.6. Mechanisms behind reduced SR Ca2+ content in heart failure.  
In heart failure, hyper-phosphorylated ryanodine receptor leads to increased Ca2+ leak and 
arrhythmias and decreased Ca2+ transients. This results in a reduced contractile force. SERCA 
is downregulated leading to reduced reuptake of Ca2+ and further contractile and Ca2+ 
dysfunction. Other contributors to reduced SR Ca2+ include decreased phosphorylation of PLN 
and up-regulated NCX-1.  
 
1.6 Calcium regulation of cell death in the cardiomyocyte  
Ca2+ also plays an important role in mitochondria-mediated cell death and is an 
important regulator of the mitochondrial permeability transition pore (mPTP).  
Previously, majority of studies focused on apoptosis as a key pathogenesis of I/R injury-
induced heart failure. However, recent studies suggested that programmed necrosis is 
actually the dominant form of cell death in CMs after I/R injury [6, 87]. Programmed 
necrosis is induced mainly by Ca2+ overload through the opening of the mPTP on the 
inner mitochondrial membrane (IMM) whereas in apoptosis, the central mitochondrial 
event is the permeabilization of the outer mitochondrial membrane (OMM) [6, 88].  
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The mPTP is a multi-protein complex that spans both the outer and inner 
mitochondrial membrane [89]. Main components of the mPTP include the voltage-
dependent anion channel (VDAC) in the outer membrane, the adenine nucleotide 
translocase (ANT) in the inner mitochondrial membrane, and cyclophilin-D (CypD) in the 
matrix [90-92]. mPTP opening leads to the following features: collapse of the 
mitochondrial membrane, cessation of ATP synthesis, redistribution of ions across the 
inner mitochondrial membrane (IMM) and increased water entry [6]. This causes 
swelling of the mitochondrial matrix and expansion of the IMM that can eventually lead 
to the rupture of the OMM and eventual cell death or programmed necrosis.   
The cellular mechanisms that contribute to the opening of the mPTP during 
ischemia are anaerobic metabolism, lactate production, and intracellular acidosis. 
These cause H+ ions to be pumped out of the cell by the Na+/H+ exchanger.  The 
Na+/K+ ATPase results in increased intracellular Na+ that is then exchanged for Ca2+ 
resulting in Ca2+ overload. The SR also contributes to increased intracellular Ca2+ due to 
CICR [6, 93]. Ca2+ overload of the mitochondria then triggers programmed necrosis and 
is the major mechanism by which programmed necrosis occurs [88].  
 
1.7 mTOR and calcium signaling and regulation 
mTOR plays a role in Ca2+ signaling via indirect regulation of the inositol 1,4,5-
trisphosphate receptor (IP3R) [94-96]. A few reports demonstrated inhibiting mTOR with 
rapamycin or a rapamycin derivative resulted in a decrease in IP3-evoked intracellular 
Ca2+ rise [95, 97]. Another study using non-excitable cells suggested that mTOR directly 
phosphorylated and activated the IP3R2 [98]. Most of these studies focused on mTOR’s 
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association with the FK506-binding proteins (FKBPs). FKBPs are accessory proteins 
that regulate both ryanodine receptors and the IP3R. Both FK506 and rapamycin 
disrupted the association between FKBPs and the IP3R and RYR by displacing FKBP 
from the channels [99]. However, fairly recently it was also discovered that mTORC2 is 
localized to the endoplasmic reticulum (ER) sub-compartment they termed 
mitochondria-associated ER membrane (MAM) and interacts with the IP3R-Grp75-
voltage dependent anion-selective channel 1 ER-mitochondrial tethering complex [5]. 
Knockdown of mTORC2 disrupted the MAM and resulted in mitochondrial defects such 
as increases in ATP production and Ca2+ uptake due to an increase in mitochondrial 
membrane potential.  
There is also additional evidence for mTOR having a role in Ca2+ signaling and 
regulation. Intracellular Ca2+ is known to regulate autophagy, a process also regulated 
by mTOR. One group reported that mTOR inhibition by rapamycin altered intracellular 
Ca2+ signaling resulting in increased ER Ca2+-store content, decreased ER Ca2+ leak 
rate, and increased Ca2+ release through IP3Rs [100]. Another study demonstrated that 
amino acids could induce a rise in intracellular Ca2+ and activate mTORC1.  All of these 
studies show mTOR may have a key role in the regulation of Ca2+ signaling, though the 
studies were performed mainly in non-excitable cells. There is yet to be a demonstration 
of a role for mTOR in Ca2+ signaling in CMs though there is substantial evidence to 
suggest mTOR has one.  
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1.8 The role of mTOR in cardiac metabolism and the metabolic syndrome 
 The metabolic syndrome has been defined as a set of metabolic risk factors 
including obesity, insulin resistance, and glucose intolerance [101]. These risk factors 
are the key factors for the later development of type 2 DM and CVD. DM is a powerful 
risk factor for the development of post-MI HF and is a common co-morbidity of HF 
accounting for 66% of mortality during the first year [102]. The Framingham study 
established the epidemiologic link between diabetes and HF demonstrating the risk of 
HF was increased 2.4 fold in men and 5-fold in woman with diabetes compared to those 
without [103]. Therefore, there is a significant need for developing therapeutics to 
prevent heart failure in diabetic patients.   
 The insulin-signaling pathway is a major potential target for therapeutic 
development as it is known to be the main cellular pathway controlling energy and 
glucose metabolism [30]. A key molecule of this pathway, mTOR may be a possible 
target for developing such therapies. mTOR has been previously shown to be 
cardioprotective and is one of the key molecules in the insulin-signaling pathway (Figure 
1.3) [2]. Dysregulated mTOR has also been implicated in both metabolic syndrome and 
DM [104]. A number of studies have shown mTOR to be involved in the regulation of 
cardiac metabolism and suggest it is upregulated in conditions of nutritional excess, 
obesity, and the metabolic syndrome [30, 39-41]. These reports seem to suggest that 
increased activation of mTOR is detrimental to the heart in these conditions; however, 
they primarily focused on mTORC1 activation and the inhibition of mTOR with 
rapamycin. In contrast, a conflicting report also using rapamycin seemed to suggest 
inhibition of mTOR with rapamycin actually prevented pancreatic beta-cell adaptation to 
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hyperglycemia and exacerbated the metabolic state in DM [105]. Supporting this study 
that mTOR is beneficial to CMs in DM is our own publication using wild type and mTOR-
Tg mice on a high fat diet. We again demonstrated that the overexpression of mTOR in 
CMs to be cardioprotective against I/R injury in a mouse model of obesity (Figure 1.7). 
Our study demonstrated that mTOR-Tg hearts were resistant to the detrimental effects 
of a HFD as the %LVDP recovery after ex vivo I/R injury was better than littermate 
controls. Peak ischemic contracture, a phenomenon resulting from increased 
intracellular Ca2+ levels and ATP depletion, and indicative of decreased recovery after 
I/R [106], was also lower in mTOR-Tg mice on a HFD than WT on a HFD [8].   
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Figure 1.7. Overexpression of cardiac mTOR prevents cardiac dysfunction after transient 
ischemia in HFD hearts. 
A. LVDP, LV dp/dt(max), LV dp/dt(min), and LVEDP over the course of the ex vivo Langendorff 
experiment. B. Quantification of the LVDP after 40 min of reperfusion compared to baseline to 
determine %LVDP recovery. C. Ischemic contracture during the 20-min ischemia period as 
determined by peak ischemic contracture (ΔLVEDP from 0 min of ischemia). N = 24 (WT-NCD), 
28 (Tg NCD), 24 (WT HFD), and 26 (Tg HFD). * p < 0.05, ** p < 0.01, and *** p < 0.001. # p < 
0.05 and ## p < 0.01. Aoyagi, et. al 2015.  
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As previously explained in section 1.4, the reason for the conflicting reports may again 
be due to the negative feedback loop where mTORC1 signaling through S6K1 
negatively regulates Akt by inhibiting insulin receptor substrate-1.  
 
1.9 Research Objectives 
 The overarching hypothesis for my dissertation is that mTOR is necessary for 
cardioprotection against pathological stressors, especially I/R injury and DM. In the 
following chapters, I will discuss the following: 
1) Determine if mTOR is necessary to protect the heart against I/R injury (Chapter 
2). To achieve this, I studied the loss of mTOR using an ex vivo I/R injury model.  
2) Determine if mTOR is necessary to maintain normal contractions and Ca2+ 
transients (Chapter 3). In this study I measured single CM function and 
intracellular Ca2+ using IonOptix.  
3) Determine if mTOR is necessary to protect the heart against I/R injury in a 
mouse model of obesity (Chapter 4). For this study, I employed the same ex vivo 
I/R model as in Chapter 2, but examined the effects of an mTOR knockout on 
cardiac function in mice that were on a high-fat diet.   
4) Discuss my findings and main conclusions from this dissertation and comment on 
future directions for this research (Chapter 5).     
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Chapter Two 
 
 
THE ROLE OF mTOR IN AN EX VIVO LANGENDORFF 
I/R INJURY MODEL  
 
2.1. Introduction 
2.1.1. Specific Aim 1: To determine the necessity of mTOR in I/R injury by using  
Ex vivo Langendorff. 
Previous studies by our laboratory using a mTOR transgenic mouse model that 
overexpressed mTOR in the CMs demonstrated that increased mTOR was sufficient to 
protect the heart against I/R injury [2]. I next wanted to demonstrate that loss of mTOR 
was necessary for cardioprotection against I/R injury. Therefore, I generated cardiac 
specific mTOR-KO (CKO) mice using a mouse strain with Cre expression under control 
of the alpha myosin heavy chain (α-MHC) promoter. To show specificity of the knockout 
I also used a tdtomato allele as a Cre reporter in the mTOR-CKO line. I then 
characterized heart function of the CKO mice at baseline by using echocardiography. 
Next, to determine whether mTOR was protective against I/R injury, I subjected these 
hearts to global ischemia using ex vivo Langendorff. Surprisingly, I found the hearts 
from the CKO mice recovered better than controls. However, CKO hearts also had 
irregular contractility that indicated they might have dysfunctional Ca2+ signaling. Based 
on these results, I investigated a functional role for mTOR in EC-coupling by using 
different stimuli such as isoproterenol and pacing.  
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2.1.2. Rationale for using tomato reporter mice 
 Determining the specificity of the knockout in CMs is difficult because the whole 
heart consists of multiple different cell types including fibroblasts, smooth muscle cells, 
and endothelial cells. In our mice, mTOR is knocked out only in the CM, which means 
the specificity is difficult to discern in the whole heart. Therefore, I also generated a 
tomato reporter mouse line in which a stop cassette behind the Rosa26 promoter 
prevents transcription of the tomato reporter gene [107]. When Cre recombinase is 
present, the LoxP sites recombine, excising the stop cassette. This then allows the 
tomato fluorescent protein to be expressed only in the cells where Cre is active. 
Breeding the reporter line with the mTORflox/flox line, this results in tomato only being 
expressed in the CMs after tamoxifen administration.      
 
2.1.3. Rationale for using ex vivo Langendorff 
 In vivo I/R injury is influenced by external factors such as neuronal, hormonal, 
and immune factors. In order to investigate the loss of mTOR alone without the 
influence of these factors, I used the ex vivo Langendorff system to determine whether 
mTOR was protective against I/R injury. Ex vivo Langendorff has several advantages 
that make it an attractive method, including its relative simplicity, experimental 
reproducibility and the ability to investigate myocardial responses in the absence of 
confounding peripheral neurohormonal factors [108]. 
 
 
 
	  24	  
2.2. Methods 
2.2.1. Animal Models 
2.2.1.1. Generation of cardiac specific mTOR knockout  
Animal experiments in this study were approved by the Institution Animal Care 
and Use Committees of the University of Hawaii (Honolulu, HI). This investigation 
conformed with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals (NIH Pub. No. 85-23, Revised 1996). Breeding pairs of floxed 
mTOR mice (mTORfl; B6.129S4-mTORtm1.2Koz/J) were obtained from Jackson 
Laboratories and inbred to generate mTORfl/fl mice, and were further inbred for more 
than ten generations before use. These mice contain LoxP sites that flank exons 1-5 of 
the mTOR gene [109] (Figure 2.1). Since these exons contain the transcription start 
site, Cre-mediated deletion of these exons results in the loss of mTOR. CM specific 
mTOR-KO mice were then generated by crossing homozygous mTORfl/fl mice with 
homozygous transgenic mTORfl/fl mice expressing a tamoxifen-inducible Cre 
recombinase fused to two mutated estrogen receptors under the transcriptional control 
of the α-myosin heavy chain promoter (α-MHCmerCremer; Tg(Myh6-cre/Esr1)1Jmk/J).    
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Figure 2.1. mTOR-KO breeding scheme.  
Homozygous mTORflox/flox with LoxP sites flanking exons 1-5 of mTOR were bred to 
homozygous mTORflox/flox and heterozygous Cre+/- mice to generate homozygous mTORfllox/flox 
mice either with or without a tamoxifen inducible Cre under control of the cardiac specific, α-
MHC promoter. These mice were then treated with tamoxifen at 6-8 weeks of age to generate 
cardiac specific mTOR-KO mice and their littermate controls. 	  
 
2.2.1.2. Generation of tomato reporter mice 
 Breeding pairs of homozygous tomato mice (tomatoR/R) were obtained from Dr. 
Michelle Tallquist’s laboratory and bred with mTORfl/fl mice to create heterozygous 
tomatoR/mTORfl mice. Heterozygous tomatoR/mTORfl mice were then bred together to 
generate homozygous tomatoR/R/mTORfl/fl mice. These mice were further interbred for 4 
generations before being crossed with mTORfl/fl/Cre+/-. The tomato mice contain LoxP 
sites that flank a stop cassette preventing transcription of the tomato gene by the 
endogenous Rosa26 promoter [107]. When Cre is active, the stop cassette is excised 
and the fluorescent tomato gene is expressed (Figure 2.2).   
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Figure 2.2. Generation of tomato reporter mice.  
Homozygous mTORflox/flox mice and homozygous Rosatomato/tomato mice were bred to generate 
double heterozygous mice (mTORflox and Rosatomato). These heterozygotes were then bred 
together to generate a 1/16th chance of getting a double homozygous (mTORflox/flox and 
Rosatomato/tomato). These double homozygous mice were then further inbred to generate the 
mTORflox/flox/Rosatomato/tomato line.  
 
	  27	  
2.2.3. Tamoxifen administration  
 Knockout of mTOR was induced by administering tamoxifen chow (Harlan 
Laboratories) to male mice ages 6-8 weeks. The chow consisted of 250 mg/kg of 
tamoxifen which provided 40 mg tamoxifen per kg body weight assuming a normal 20-
25 g body weight and 3-4 g intake. Mice were kept on this diet for two weeks before a 
normal chow diet was resumed.  
 
2.2.4. Echocardiography 
 Echocardiography was performed on non-anesthetized mice using a 13L high-
frequency linear transducer (10 MHz, VingMed 5, GE Medical Services) as previously 
described [7]. I measured left ventricular interior diameter dimension (LVIDd) and % 
fractional shortening (%FS) as analysis of cardiac structure and function for control and 
mTOR-CKO mice at baseline. 
 
2.2.5. Isolation of adult murine ventricular myocytes 
Control or mTOR-KO male mice (8-12 weeks of age) were anesthetized with 
2,2,2-tribromoethanol (TBE). The heart was quickly removed from the chest and 
retrograde perfused at a constant flow rate of 3 mL/min at 37°C for 2-3 minutes with a 
Ca2+-free bicarbonate based buffer containing 120 mM NaCl, 5.4 mM KCl, 1.2 mM 
MgSO4, 1.2 NaH2PO4, 5.6 mM glucose, 20 mM NaHCO3, 10 mM 2,3-butanedione 
monoxime (BDM; Sigma) and 5 mM taurine (Sigma), gassed with 95% O2-5%CO2 to 
washout remaining Ca2+ in the heart. Following perfusion with the Ca2+-free buffer, 
enzymatic digestion was initiated by perfusing with a collagenase buffer containing 0.4 
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mg/mL collagenase type B (Roche), 0.3 mg/mL collagenase type D (Roche), and 0.03 
mg/mL protease type XIV (Sigma Aldrich) in 50 mL of Ca2+ free perfusion buffer. All 
solutions were filtered with a 0.2 µM filter. Hearts were perfused with the collagenase 
buffer for 15-20 minutes until the heart was fully digested. Collagenase buffer was then 
washed out by perfusing again with Ca2+-free buffer for 2-3 minutes. CMs were isolated 
by mechanically teasing the cells apart. They were then gently triturated with a plastic 
transfer pipette and were filtered using a sterile 100 µM filter [110]. Myocytes were then 
allowed to settle by gravity. CMs were then snap frozen in liquid nitrogen for later use in 
Western blot analysis.  
Figure 2.3. Adult murine CMs isolated from C57BL6 mice.  
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2.2.6. Western blot analysis 
Hearts were harvested, snap frozen, and crushed in liquid nitrogen. Tissue was 
homogenized in ice-cold lysis buffer (Cell Signaling, Danvers, MA) as previously 
described [2, 7]. Isolated CMs were obtained as described above. The CMs were snap 
frozen and lysed in ice-cold lysis buffer (Cell Signaling, Danvers, MA). Protein 
concentrations were measure using the Bradford method (BioRad, Hercules, CA). SDS-
PAGE was performed under reducing conditions on 4-20% gradient gels (Bio-Rad). 
Proteins were then transferred to a polyvinylidene fluoride (PVDF) transfer membrane 
with fluorescent capability (Millipore). Blots were then incubated with primary antibodies 
overnight for 18-20 h at 4°C followed by incubating with either a green fluorescent 
donkey anti-mouse secondary antibody or a red fluorescent goat anti-rabbit secondary 
antibody. Signal was detected using a fluorescent reader and Image Studio by Licor. 
Primary antibodies to mTOR (Cell Signaling), phospho and total S6 (Cell Signaling), 
phospho-Akt (Cell Signaling), Akt (Santa Cruz), IP3R2 (Millipore), VDAC (Cell 
Signaling), Cre (Millipore), and Gapdh (Santa Cruz) were used for immunoblot analysis. 
 
2.2.7. Analysis of tomato reporter mice. 
 Tomato reporter mice ages 12-20 weeks were heparinized with 1000 IU/kg and 
anesthetized with 250 mg/kg 2,2,2-tribromoethanol (TBE). Whole hearts were excised 
and placed in optimal cutting temperature (O.C.T.) compound and snap-frozen at -80°C. 
Five µM sections were cut and placed on Superfrost Plus microscope slides (Thermo 
Scientific). Slides were stained with the nuclear stain 4',6-diamidino-2-phenylindole 
[(DAPI), Life Technologies]. They were then covered with Fluoromount-G (Southern 
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Biotech) in order to protect the fluorescent expression of the sections and visualized 
using an immunofluorescence microscope.  
 
2.2.8. Ex vivo I/R in Langendorff perfused hearts.  
Male controls and mTOR-CKO mice ages 12-20 weeks old were heparinized with 
1000IU/kg and anesthetized with 250 mg/kg 2,2,2-tribromoethanol (TBE) diluted in 
sterile PBS. Hearts were excised and subjected to an ex vivo Langendorff perfusion 
model as previously described (Figure 2.4) [2, 111]. After retrograde perfusion was 
established at a constant pressure (80 mmHg), hearts were perfused with a modified 
Krebs-Henseleit buffer (11 mM glucose, 118 mM NaCl, 4.7 mM KCl, 2.0 mM CaCl2, 1.2 
mM MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3, and 0.5 mM EDTA) equilibrated with 
95% O2-5%CO2 at 37°C to yield a pH of 7.4. A water-filled balloon catheter was 
introduced into the left ventricle (LV) to record LV pressure (PowerLab, AD Instruments, 
Denver, CO). I measured the volume of the coronary sinus effluent in the collected 
perfusate to determine the coronary flow rate. For the ex vivo I/R model, hearts were 
perfused for 15 min, and the flow was eliminated for 20 min, followed by reperfusion for 
40 min. The peak ischemic contracture during the 20-min ischemia period was 
determined by the alteration of LV end-diastolic pressure (LVEDP) as previously 
reported [2, 112]. To calculate the percent left ventricular developed pressure recovery 
(%LVDP), the LVDP was compared at baseline and at 10, 20, 30, and 40 minutes of 
reperfusion.     
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Figure 2.4. Picture of a heart hung on the ex vivo Langendorff apparatus with balloon 
inserted into the LV.  
 
 
2.2.9. Drug treatment protocol for ex vivo Langendorff perfused hearts.  
Wild-type (C57BL/6) mice were treated as described above in section 2.2.8. 
Hearts were perfused for 10 minutes and treated with 100 nM Torin1 for 20 minutes. 
The flow was eliminated for 20 minutes followed by 40 minutes of reperfusion.  
 
2.2.10. Pacing protocol for ex vivo Langendorff perfused hearts.  
 Hearts from CKO and control mice were subjected to ex vivo Langendorff as 
described in 2.2.8. They were paced prior to ischemia at increasing pacing rates of 5, 6, 
7, 8, 9, and 10 Hz for 15 seconds each at each pacing frequency followed by a recovery 
period of one minute. After the recovery period, the hearts were subjected to global 
ischemia for 20 minutes followed by 40 minutes of reperfusion.  
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2.2.11. Isoproterenol challenge of ex vivo Langendorff perfused hearts 
 Hearts were harvested from CKO and control mice and subjected to ex vivo 
Langendorff as described above in 2.2.8. The hearts were treated with 1 µM 
isoproterenol at the start of equilibration for 15 minutes. The hearts were subjected to 
the normal 20 minutes of ischemia before being perfused again with 1 µM isoproterenol 
at the start of reperfusion for 30 minutes. After 30 minutes, the hearts were switched to 
a buffer without isoproterenol for 10 minutes.  
 
2.2.12. Biological analysis of ex vivo perfused hearts 
 Effluent was collected at 40 minutes of reperfusion and concentrated with an 
Amicon Ultra-0.5 centrifugal filter (3K device, Millipore, Billerica, MA). Samples 
concentrated from the effluent were analyzed with an enzyme activity kit for creatine 
kinase (RayBiotech). 
 
2.2.13. Calculation for average variance of contractions 
 To calculate the average variance of contraction, I took the average LVDP and 
then took the change from that average to determine the variance for four 10-minute 
intervals during reperfusion. The formula I used was as follows:   
 
 
The variance for each group was averaged. 
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2.2.14. Calculation for peak ischemic contracture (Δ mmHg) and time to peak ischemic 
contracture. 
 To calculate the peak ischemia contracture, I took the change in ΔLVEDP from 0 
min of ischemia to the peak LVEDP as previously described [106]. To determine the 
time to peak ischemic contracture, I found the time it took to reach the peak ischemic 
contracture using the start of ischemia as time 0.   
 
 
2.2.15. Insulin stimulation of ex vivo Langendorff perfused hearts.  
 Mice 12-20 weeks of age were again subjected to ex vivo Langendorff as 
described in section 2.2.7. At the start of reperfusion they were treated with 0.1 µg/mL 
of insulin for the entire duration of reperfusion.  
 
2.2.16. Subcellular fractionation of whole heart tissue.  
 Hearts were isolated from control or mTOR-KO mice 12-20 weeks of age and 
placed in fiber relaxation buffer (100 mM KCl/5 mM EGTA/5 mM HEPES/KOH, pH=7.5) 
for 10 minutes. Hearts were dried and homogenized with a glass dunce homogenizer in 
SPHEM-A buffer (250 mM sucrose/20 mM HEPES/KOH, pH=7.5/10 mM KCl, 1.5 mM 
MgCl/1.5 mM Na EGTA/2.5 mM Na EDTA/1 mM DTT/0.1 mM PMSF). The homogenate 
was centrifuged at 2,700 rpm for 10 min at 4C. The result supernatant was collected 
and pellets were washed with sucrose-free buffer (SPHEM-A buffer without sucrose). 
This pellet was saved and labeled as the “nuclear fraction.” The supernatant was then 
centrifuged at 10,200 rpm for 15 min at 4C. Again the resulting supernatant was 
collected and the pellet was washed and resuspended with 1 mL SPHEM-A buffer. This 
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fraction was centrifuged at 6,137 rpm for 15 min at 4°C. The supernatant from this 
fraction was discarded and the pellet was saved as the “mito heavy fraction.” The 
supernatant that was collected in the previous step was then centrifuged at 29,000 rpm. 
The resulting supernatant was collected and labeled as the “cytosolic fraction” while the 
pellet was labeled as the “mito/SR fraction” [113].  
 
2.2.17. Statistical analysis 
 Results were analyzed using Graph Pad’s PRISM software. Statistical tests were 
applied according to the experimental design as indicated in the figure legends. For 
comparisons of two groups, a student t-test was applied. For comparison of multiple 
groups, one-way ANOVA was used. Tukey’s post hoc test was used as a post-test for 
one-way ANOVA. P values are also shown in the figures or graphs. All results are 
reported as means ± SEM.  
 
2.3. Results 
2.3.1. Knockout of mTOR is cardiomyocyte specific. 
First, in order to confirm lower levels of cardiac mTOR expression in our 
tamoxifen inducible mTOR-CKO mice, I isolated CMs from control and CKO mice using 
the method described in section 2.2.4. Western blot analysis of control and CKO mice 
using whole heart tissue and isolated CMs showed significantly lower levels of mTOR in 
CKO hearts in both the whole heart and isolated CMs as compared to controls (Figure 
2.3A). For further confirmation, I also generated a tomato reporter line as explained in 
section 2.2.1.2. At 12-14 weeks of age, I excised whole hearts from these mice as 
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described in section 2.2.6 and examined the tomato expression using a fluorescent 
microscope. This further demonstrated that only CKO mice expressed the tomato 
reporter and that expression of tomato was only in the CMs (Figure 2.3B). Smooth 
muscle cells, fibroblasts, and other cell types within the heart did not express the tomato 
gene.  
 
Figure 2.5 Knockout of mTOR is cardiomyocyte specific. 
A) Right. Representative immunoblot showing a small decrease in mTOR expression in whole 
hearts and a significant decrease in the expression of mTOR in isolated CMs and in the whole 
heart compared to control. Left. Quantification of the amount of mTOR in whole heart and 
isolated CMs. N = 6 for all groups. B) Fluorescent images demonstrated expression of the 
tomato reporter gene is only in mice with Cre. Cre negative mice did not express the tomato 
gene.   
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2.3.2. mTOR-KO mice have normal heart sizes and baseline function.  
  To determine if mTOR knockout affects cardiac structure and function, I 
measured the size of mTOR-CKO heart versus body size, and baseline physiology, and 
compared them to littermate controls. Hearts were weighed and normalized to tibia 
length. mTOR-CKO mice showed no difference in heart size or body weight compared 
to controls (Table 2.1 and Figure 2.6A). Control and CKO mice were then also 
evaluated for baseline function via echocardiography (Table 2 and Figure 2.6B). There 
was no significant difference in percent fractional shortening (%FS) or left ventricular 
end diastolic internal dimension (LVIDd) (Figure 2.6C). However, left ventricular 
posterior wall diameter (LVPWd) was significantly decreased in CKO mice, potentially 
showing a decrease in ventricular wall thickness after mTOR knockout. Nevertheless, it 
did not appear to significantly affect cardiac function of the mice at baseline as there 
was no significant difference in %FS or ejection fraction (EF). Overall, these results 
show the cardiac structure and function of CKO mice are normal at baseline.  
Table 1. Body weight, heart weight, and heart weight:tibia length (HW:TB) ratio of control 
and mTOR-KO mice.  
 Control mTOR-CKO 
Body Weight 26.93 ± 0.39 26.18 ± 0.42 
Heart Weight 0.198 ± 0.006 0.193 ± 0.006 
HW:TB 0.00883 ± 0.00032 0.00845 ± 0.00024 	  
There was no significant difference in body weight, heart weight, and HW:TB between controls 
and CKO mice. N = 24 for both groups.  
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Table 2. Baseline echocardiograph parameters. 
 Control mTOR-KO 
E’-Vel 37.28 ± 2.45 35.32 ± 1.02 
MV Decel Time 19.39 ± 1.57 18.33 ± 1.04 
MV E-Vel 790.28 ± 23.79 764.41 ± 23.92 
E/E’ 21.87 ± 1.38 21.39 ± 0.65 
IVSD 0.690 ± 0.014 0.657 ± 0.025 
LVIDd 3.03 ± 0.028 3.02 ± 0.069 
LVPWd 0.803 ± 0.014 0.716 ± 0.017 * p < 0.01 
LVIDs 1.19 ± 0.078 1.39 ± 0.97 
EF 91.14 ± 1.40 84.91 ± 1.75 
%FS 61.13% ± 2.28 53.39% ± 2.90 
HR 710.71 ± 10.48 710.62 ± 4.57 	  
A list of baseline echocardiograph parameters from control and mTOR-KO mice. Only LVPWd 
of the knockdown mice was significantly different although functional parameters such as EF 
and %FS were not significantly different between the two groups. N = 7 in each group.   
 
 
Figure 2.6. mTOR-CKO mice have normal sized hearts and normal baseline cardiac 
function.  
A. Representative pictures of whole hearts isolated from control and CKO mice. CKO mice 
exhibited no gross abnormalities and are normal in size. B. Representative M-mode traces from 
baseline echocardiography analysis of control and CKO mice. CKO mice had normal 
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contractions that were similar to controls. C. Left. CKO mice LVIDd was comparable to controls. 
Right. %FS was similar between control and CKO mice. N = 7 in each group.  
 
 
2.3.3. Torin1 significantly decreases the percent left ventricular developed pressure 
(%LVDP) recovery of wild-type Langendorff perfused hearts.  
 To show the effects that acute inhibition of mTOR has on the recovery of 
C57BL/6 wild-type hearts after I/R injury, I treated wild-type mice with Torin1, an 
mTORC1 and mTORC2 inhibitor [114]. I subjected the mice to ex vivo Langendorff and 
treated them with 100 nM of Torin1 for 10 minutes prior to ischemia as described in 
section 2.2.7. Treatment of wild-type mice with Torin1 resulted in significantly decreased 
%LVDP recovery (Figure 2.7). This showed that acute inhibition of mTORC1 and 
mTORC2 was detrimental to the heart post-I/R injury and was consistent with our in vivo 
data (Figure 1.4).   
 
 
Figure 2.7. Torin1 treatment significantly decreases %LVDP recovery in wild-type mice.   
Wild-type C57Bl6 mice were subjected to ex vivo Langendorff and were either treated with 100 
nM Torin1 or not treated. A) Representative tracings from the torin1 experiments. B) 
Quantification of the %LVDP recovery of wild-type mice treated with or without Torin1. The 
LVDP at baseline and reperfusion were compared to calculate the %LVDP. Torin1 treatment 
significantly decreased the recovery of wild-type Langendorff perfused hearts N=7 (WT) and 8 
(WT + torin1). p < 0.05 by student T-test.     
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2.3.4. Torin1 treatment decreases downstream mTOR signaling.  
 To verify that Torin1 treatment was effective, I performed immunoblotting to 
determine if activation of both mTORC1 and mTORC2 were diminished in the wild-type 
mice that were given insulin as p-Akt is downstream of mTORC2 and p-S6 is 
downstream of mTORC1. I found that both p-Akt and p-S6 expression was significantly 
decreased in wild-type mice treated with Torin1 (Figure 2.8). This demonstrated my 
treatment with Torin1 was effective even though expression of mTOR was not 
significantly decreased between the two groups.  
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Figure 2.8. Torin1 treatment decreases downstream signaling of both mTORC 
complexes.  
A) Immunoblot showing downstream targets (p-Akt and p-S6) of mTORC1 and mTORC2 are 
significantly decreased in hearts treated with Torin1. B) Densitrometric analysis of mTOR, p-Akt, 
and p-S6. mTOR was normalized to Gapdh. p-Akt was normalized to total Akt and p-S6 was 
normalized to total S6. P-values are displayed on graphs as determined by student’s t-test. N = 
3 for all groups. 
 
2.3.5. Baseline ex vivo Langendorff parameters show control and mTOR-KO mice 
hearts have similar cardiac function prior to I/R injury. 
 Torin1 treatment of WT mice appeared to suggest mTOR was cardioprotective 
against I/R injury. Therefore, I used a genetic model to determine if mTOR activation in 
both complexes is required for protecting the heart against I/R injury. For this I 
	  41	  
subjected cardiac specific mTOR-KO mice and littermate controls to ex vivo 
Langendorff. To ensure there were no gross abnormalities between the control and 
CKO hearts at baseline, I examined both baseline parameters prior to subjecting them 
to global ischemia (Table 3).  
Table 3. Baseline ex vivo Langendorff parameters. 
 Control mTOR-CKO 
Dp/Dt (max) 5824.36 ± 1040.97 5288.40 ± 630.57 
Dp/Dt (min) -3544.57 ± 242.41 -3238.95 ± 347.38 
LVSP (base) mmHg  113.04 ± 13.56  113.07 ± 8.93 
LVEDP (base) mmHg 6.45 ± 1.01 5.81 ± 1.15 
LVDP (base) mmHg 106.67 ± 13.95  107.26 ± 9.83 
Heart Rate (bpm) 369.83 ± 31.92  343.45 ± 18.32 
Coronary Flow (mL/min) 4.30 ± 0.967  6.41 ± 0.856 
 
Control and mTOR-CKO hearts have relatively the same cardiac function at baseline, prior to 
I/R injury. There was no statistically significant difference in beginning LVDP, heart rate, dp/dt 
(max) or dp/dt (min), or coronary flow rate.   
 
 
 
2.3.6. Hearts from mTOR-KO mice exhibit better percent left ventricular developed 
pressure recovery (%LVDP) after I/R injury but increased variance of contractions 
compared to controls.  
 Baseline analysis of mTOR-KO and control hearts showed no significant 
difference prior to I/R injury. Therefore, I evaluated the loss of mTOR in I/R injury using 
ex vivo Langendorff. Unexpectedly, CKO and control hearts displayed significantly 
better LVDP recovery versus controls (Figure 2.9). This was a surprising result as the in 
vivo data clearly shows the CKO mice do not recover as well after I/R injury and acute 
inhibition of mTOR was also shown to be harmful to the heart in a global ischemia-
reperfusion model. However, I did notice that the CKO hearts appeared to have 
increased irregular contractility compared to controls (Figure 2.10). I calculated the 
average variance of contractions (Section 2.2.11) and determined that mTOR-CKO 
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hearts had significantly increased variance during the first ten minutes and during the 
last ten minutes of reperfusion. The increased variance I observed in the CKO mice 
during reperfusion allowed me to formulate the hypothesis that mTOR has a possible 
role in EC-coupling and Ca2+ signaling.       
 
Figure 2.9. mTOR-CKO hearts have better %LVDP recovery after ex vivo I/R. 
A. Left. Representative tracing showing LVDP throughout the Langendorff experiment. B. 
Quantification of LVDP at baseline and after every 10 min of reperfusion. C. Quantification of 
the %LVDP recovery for control vs. CKO. CKO hearts recover significantly better than controls. 
*p < 0.05 by student t-test. All other p-values displayed on graphs. N = 7 for each group. 
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Figure 2.10. mTOR-KO hearts have significantly increased average variance of 
contractions.  
A) Left. Representative tracing showing the difference in peak sizes between the control and 
CKO hearts taken over a 5 second period. mTOR-KO hearts had noticeably different sized 
peaks while controls were relatively the same. Right. Representative tracing showing the 
increased variance of contractions mTOR-KO hearts have after I/R injury. Representative 
tracings were taken over a 1-minute period during the last ten minutes of reperfusion. B) 
Quantification of the average variance of contractions. mTOR-KO hearts had significantly 
increased average variance during the first 10 minutes and last 10 minutes of reperfusion 
compared to controls. N=7 for each group. P-values listed on graph as determined by student’s 
t-test.  
 
2.3.7. mTOR-KO hearts have significantly less cell death than controls after ex vivo I/R.  
  To verify that the decrease in recovery was not artificial due to the Langendorff 
system, I determined the amount of the myocardial injury marker, creatine kinase (CK) 
released during the ex vivo experiment. Using an enzyme assay kit, I measured the 
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amount of creatine kinase in the buffer collected from control and CKO hearts. I found 
mTOR-CKO hearts significantly released less CK released than controls indicating less 
cell death than control hearts (Figure 2.11). 	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11. mTOR-KO hearts have a significantly decreased marker of myocardial 
damage compared with controls.  
The amount of the myocardial injury marker, creatine kinase released after ischemia and 40 
minutes of reperfusion was measured using an enzyme assay kit. CKO mice produced 
significantly less creatine kinase than controls. N=7 for each group. P-value shown on graph as 
determined by student’s t-test.  
 
 
2.3.8. Isoproterenol challenge of CKO hearts does not significantly affect LVDP 
recovery.  
 Due to the discrepancy between the in vivo I/R and ex vivo data, I challenged the 
mice using the β-adrenergic stimulator, isoproterenol. Ex vivo models do not have 
neuronal or hormonal stimulation and I hypothesized beta-adrenergic stimulation may 
be a missing factor that could explain the better recovery of the CKO mice using ex vivo 
Langendorff. Additionally, because of the increased variance of contractions, I 
speculated there might be a potential role for mTOR in Ca2+ signaling. Binding of 
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isoproterenol to both β1 and β2 adrenergic receptors activates PKA, which in turn 
causes increased phosphorylation of the RYR and can result in “leaky” channels that 
deplete SR Ca2+ stores. Isoproterenol has been used by other researchers in ex vivo 
Langendorff to investigate Ca2+ leakage through the RYR [115, 116]. I gave the hearts 1 
µM isoproterenol at the start of equilibration and then again at the start of reperfusion 
until the last ten minutes. Then the buffer was switched to a normal KHB buffer without 
isoproterenol. The CKO hearts had decreased LVDP recovery when stimulated with 
isoproterenol. However, the recovery of the CKO hearts was relatively the same as 
controls (Figure 2.12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12. Isoproterenol stimulation decreased recovery of both control and CKO 
hearts but does not cause CKO hearts to recover significantly worse than controls. 
Quantification of %LVDP recovery of CON and CKO hearts with and without 1 µM isoproterenol 
stimulation. N = 4 (CON) and N = 5 (CKO). There was no significant statistical difference 
between the control and CKO groups. P-value = 0.77 
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2.3.9. mTOR-KO hearts exhibit cardiac alternans at baseline. 
 Pacing also affects EC-Coupling and results in the increased activation of 
calcium/calmodulin-dependent serine/threonine kinase-δ (CAMKIIδ) and increased 
phosphorylation of PLN [117]. Therefore, I next decided to pace the hearts to determine 
if pacing would reveal any alterations in Ca2+ handling and/or contractility. CON and 
CKO hearts were again subjected to ex vivo Langendorff. Hearts were paced prior to 
ischemia for 15 seconds at each frequency (5 to 10 Hz). Hearts were then allowed to 
recover with no pacing for 1 minute before undergoing the normal 20 minutes of 
ischemia, followed by 40 min of reperfusion. mTOR-CKO hearts exhibited cardiac 
alternans at baseline (Table 4 and Figure 2.13). Cardiac alternans is a periodic beat-to-
beat oscillation in electrical activity at a constant heart rate. It is caused by a number of 
different factors; however, alternans always originate from disturbances of the coupling 
of the membrane voltage and intracellular Ca2+ [118]. As shown in Table 4, on average, 
CKO mice displayed cardiac alternans more consistently and at lower frequencies than 
controls.  
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Table 4. CKO hearts display cardiac alternans more consistently and at lower 
frequencies versus controls.  
 5 Hz 6 Hz 7 Hz 8 Hz 9 Hz 10 Hz 
CONTROL #1 N N N N N N 
CONTROL #2 N N N N N N 
CONTROL #3 N N N N N N 
CONTROL #4 N N N N Y Y 
CONTROL #5 N N N N Y Y 
mTOR-CKO #1 N N Y Y Y Y 
mTOR-CKO #2 N N N Y Y Y 
mTOR-CKO #3 N N Y Y Y Y 
mTOR-CKO #4 N N N N Y Y 
 
Table showing each heart used in this experiment. N is for no cardiac alternans, Y is for cardiac 
alternans.  
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Figure 2.13. mTOR-CKO hearts display cardiac alternans at baseline.  
Hearts were paced at increasing frequencies from 5 to 10 Hz for 15 seconds at each frequency. 
A) Representative tracing of the changes in LVDP during 8 Hz pacing. Pacing revealed CKO 
hearts had cardiac alternans when paced at 8 Hz or higher. B) Close up view of the traces 
shown above along with the ECG tracings. N=5 for each group.   
 
 
2.3.10. Pacing has no effect on LVDP recovery of control and CKO hearts.  
 To determine if pacing had any effect on the LVDP recovery of control and CKO 
hearts I compared the baseline LVDP to the LVDP at the end of 40 minutes of 
reperfusion to determine the %LVDP recovery. I found that pacing had no effect overall 
on the recovery of the control and CKO hearts as the CKO hearts still recovered 
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significantly better than the controls despite displaying cardiac alternans at baseline 
(Figure 2.14).  
 
Figure 2.14. Pacing does not affect %LVDP recovery of mTOR-CKO hearts. 
A) Representative tracings of a full Langendorff experiment from a control heart and an mTOR-
CKO heart. B) Quantification of the change in LVDP from baseline over the course of 
reperfusion. C) Comparison of the LVDP after 40 minutes of reperfusion to baseline LVDP to 
determine %LVDP. ** p < 0.01. P-value for %LVDP is displayed on graph. N = 9 (CON) and 8 
(CKO).  
 
2.3.11. Pacing before reperfusion results in decreased ischemic contracture of CKO 
hearts.  
 The cardiac alternans displayed at baseline by the CKO hearts suggested that 
the SR Ca2+ concentration of the CKO hearts was different than the control hearts. 
Consequently, I examined the ischemic contracture of hearts on the pacing protocol. I 
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found the CKO hearts had significantly decreased peak ischemic contracture (Δ mmHg) 
and significantly increased time to peak ischemic contracture (Figure 2.15). The 
significance of ischemic contracture is that it is due to the depletion of ATP but also the 
rise of intracellular Ca2+ [119, 120]. Lower baseline SR Ca2+ levels could be a reason for 
the decreased peak ischemic contracture I observed in the CKO hearts. 
 
Figure 2.15. CKO hearts have significantly decreased peak ischemic contracture as well 
as well as significantly increased time to peak ischemic contracture.  
A) Quantification of peak ischemic contracture. B) Quantification of time to peak ischemic 
contracture. N = 9 (CON) and 8 (CKO). P-values are displayed on graphs. 
 
 
 
 
 
  
 
 
 
 
	  51	  
2.3.12.  mTOR-KO mice hearts recover worse when treated with insulin during 
reperfusion.  
As mentioned in section 2.1.3, hearts subjected to ex vivo Langendorff are 
missing a number of systemic factors. Therefore, because mTOR is part of the insulin-
signaling pathway, I tested the effect of insulin on our mTOR-CKO mice. I subjected 
control and CKO mice to the same insulin and ex vivo protocol (Section 2.2.4). I found 
insulin to be slightly cardioprotective in our control mice though the result was not 
significant. However, in the CKO mice I found that insulin appeared to significantly 
decrease the %LVDP recovery when given at reperfusion although it did not lower the 
recovery significantly more than the controls (Figure 2.16). 
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Figure 2.16. Insulin administered at reperfusion significantly decreases recovery of the 
mTOR-KO hearts.  
A) Representative tracings of LVDP over the course of the Langendorff experiment. Insulin 
administered at reperfusion appeared to decrease the recovery of mTOR-KO hearts. B) 
Comparison of LVDP at baseline and after 40 minutes of reperfusion to determine %LVDP. 
CKO N = 6 (CON), 3 (CKO), 6 (CON + Insulin), and 4 (CKO + Insulin). P-values are listed on 
graph as determined by one-way ANOVA and Tukey’s post hoc test.  
 
2.3.13. IP3R2 expression is significantly decreased in the SR/mito fractions of mTOR-
KO hearts.  
 It is known that insulin activates Ca2+ release through the IP3R and promotes 
mitochondrial Ca2+ uptake [121, 122]. Since mTOR is known to localize at mitochondria 
associated membranes, I investigated the other Ca2+ release channel in the heart, the 
IP3R2 to determine if the expression was changed. Decreased expression of IP3R2 at 
the SR/mito has previously been shown to be downregulated at MAMs in mouse 
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embryonic fibroblasts (MEFs) that have RICTOR knocked down [5]. mTOR has also 
been shown to phosphorylate the IP3R2 in non-excitable pancreatic AR4-2J cells [98]. 
Therefore, alteration of the IP3R may be the reason for the improved recovery I saw 
initially without insulin stimulation but substantially mitigated function with insulin 
treatment at reperfusion. To assess the IP3R expression in CKO and control hearts, I 
followed the subcellular fractionation protocol detailed in section 2.2.16 to obtain the 
SR/mito fraction. I immunoblotted IP3R2 and found the expression of the IP3R2 to be 
significantly decreased in mTOR-KO hearts when normalized to VDAC (Figure 2.17).   
	  
Figure 2.17. IP3R protein level is reduced in the SR/mito fraction of CKO hearts.  
Hearts from CKO and control mice were harvested and subjected to a subcellular fractionation 
protocol. A) Western blot showing decreased IP3R expression in the SR/mito fraction of mTOR-
KO hearts. B) Quantification of the fold change decrease of IP3R expression. Gapdh was used 
to determine the purity of the fractions while VDAC was used as a loading control. Blots were 
analyzed using ImageJ software. N=6 (control) and 5 (CKO). p-value displayed on graph as 
determined by student t-test. 	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2.4. Discussion 
2.4.1. Summary and interpretation of results 
  Based on our previous studies using mTOR-Tg mice in in vivo and ex vivo I/R 
injury, in the study using the mTOR-CKO, I anticipated that mTOR was necessary for 
cardioprotection against I/R injury. The in vivo data clearly demonstrated mTOR was 
necessary for protecting CMs from cell death following I/R injury (Figure 1.4). 
Accordingly, I also anticipated the mTOR-CKO mice would have significantly worse 
recovery after ex vivo I/R injury. Acute inhibition of mTOR with Torin1 in our ex vivo 
model supported our in vivo findings (Figure 2.7). However, I was surprised to find the 
CKO hearts had significantly better recovery after ex vivo I/R injury as well as a 
significant decrease in release of the myocardial injury marker, creatine kinase (Figures 
2.9 and 2.11). I hypothesized the reason for this discrepancy between the in vivo and ex 
vivo models could be due to either a lack of systemic stimulation in the ex vivo system 
or due to a change in one or more of the proteins involved in EC-Coupling. Several 
publications have already suggested a role for mTOR in Ca2+ signaling in other cell 
types [5, 97, 100, 123, 124] and one report has shown mTOR to be localized at 
mitochondrial associated ER membranes [5, 97, 100, 123, 124]. Additionally, my own 
data showing the CKO hearts had irregular contractility following I/R injury was another 
clue hearts from mTOR-CKO mice may have abnormal contractile function and Ca2+ 
transients (Figure 2.10).   
 Based on previous studies and my data, I examined the role of mTOR in EC-
coupling in the CKO hearts treated with isoproterenol that stimulates SR Ca2+ release. I 
observed no difference in the recovery between control and CKO hearts using this 
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method of stimulation although isoproterenol resulted in a lower recovery for both 
control and CKO hearts than normal (Figure 2.12). This suggested that hyper-
phosphorylation of the ryanodine receptor is not the major EC-coupling protein 
alteration in CKO CMs. Therefore, I applied electrical stimulation to pace the hearts to 
investigate another potential mechanism responsible for the irregular contractility of the 
CKO hearts. Pacing has been shown to activate CAMKIIδ and also increase 
phosphorylation of PLN [117, 125].  This would allow me to assess if there was an 
alteration in PLN in CKO hearts. I noticed that the mTOR-KO hearts displayed cardiac 
alternans at baseline but also had significantly decreased peak ischemic contracture as 
well as time to peak ischemic contracture (Figures 2.13 and 2.15). Ischemic contracture 
is the result of decreased ATP and increased Ca2+ levels during ischemia. However, I 
did not find any evidence to suggest that PLN was altered in the CKO hearts and was 
responsible for the decreased peak ischemic contracture and time to peak ischemic 
contracture. It is likely that mechanisms other than the hyper-phosphorylation of the 
RYR2 and PLN result in the improved recovery for the CKO hearts.   
One possible mechanism may involve insulin since mTOR is a major component 
of insulin signaling. It is known that insulin stimulates mitochondrial fusion and function 
in CMs via the Akt-mTOR-NFkB-Opa-1 signaling pathway [121, 122, 126]. As a result, I 
stimulated the hearts with insulin at reperfusion (Figure 2.16). As expected, insulin was 
detrimental to the CKO hearts but in the same proportion as control hearts. 
After the insulin study, I investigated the IP3R since none of the traditional 
proteins involved in EC-coupling and Ca2+ handling seemed to be altered in our mouse 
models. In addition, insulin has been shown to activate Ca2+ release from the IP3R in 
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striated muscle cell promoting mitochondrial Ca2+ uptake [121]. mTOR is known to 
associate with MAMs and I hypothesized that decreased IP3R expression could lead to 
MAM destabilization. The additional Ca2+ entering the cytosol should increase uptake 
into the mitochondria due to insulin stimulation. Since the MAM is already destabilized, 
this should result in increased cell death due to Ca2+ overload, which may explain the 
lowered recovery I observed in our CKO hearts after insulin was given at reperfusion. 
Lowered IP3R expression could also explain the better recovery in the initial ex vivo 
studies, as there would be less Ca2+ released due to a decrease in IP3R expression. 
Indeed, when I compared the SR/mito fractions of the CKO hearts compared with 
controls, I found IP3R expression to be significantly decreased (Figure 2.17). As this 
was a preliminary study, I did not verify creatine kinase release from the hearts 
stimulated with insulin, nor did I check the mRNA levels of the IP3R. More thorough and 
stringent investigation is therefore needed to determine if this really is the mechanism 
behind the improved recovery ex vivo. 
In conclusion, even though the CKO hearts recovered better than control hearts 
in a Langendorff model of global ischemia and reperfusion, it does not indicate that less 
expression of mTOR is cardioprotective against I/R injury. Since there are no 
neurohormonal factors such as insulin in ex vivo hearts, in certain condition, missing 
systemic factors would affect cardiac recover after I/R injury in this model. The 
decreased recovery of the CKO hearts seen after insulin stimulation and the in vivo data 
suggests mTOR plays an important cardioprotective role against I/R injury, although its 
mechanism remains unclear.  
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Chapter Three 
 
 
THE ROLE OF mTOR IN VITRO IN CALCIUM 
SIGNALING AND EC-COUPLING 
 
3.1. Introduction 
3.1.2. Specific Aim 2: To define the role of mTOR in cardiomyocyte Ca2+ signaling 
and EC-coupling. 
 I next determined if cardiac mTOR regulates Ca2+ transients and contraction in 
adult murine CMs, a necessity in the heart. A key marker of heart failure is defective 
Ca2+ handling leading to arrhythmias and contractile dysfunction [127]. Defective Ca2+ 
transients are the result of many different pathogenic mechanisms including hyper-
phosphorylation of the ryanodine receptor, decreased SERCA expression, and 
increased phosphorylation of PLN [128]. mTOR, an important cell regulator of many 
processes, has already been shown to be involved in Ca2+ regulation as previously 
mentioned in section 1.7. In mouse embryonic fibroblasts, mTORC2 has been shown to 
associate with the ER and mitochondrial associated membranes (MAMs). Disruption of 
mTORC2 was associated with a number of mitochondrial defects including an increased 
Ca2+ uptake [5]. Another group demonstrated that rapamycin inhibition of mTOR 
impaired Ca2+ release from inositol 1,4,5-trisphophate receptors (IP3Rs) in vascular 
smooth muscle [95]. Several other groups also confirmed mTOR’s role in modulating 
the IP3R (section 1.7).  
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 Therefore, based on this literature and on our preliminary data, I hypothesized 
that mTOR is necessary to maintain normal Ca2+ transients and EC-coupling [5]. 
Accordingly, I investigated Ca2+ transients in the control and CKO CMs. To do this, I 
isolated CMs as specified in section 2.2.4 and 3.2.2. The cells were loaded with the 
Ca2+ indicator, Fura-2-AM as described in section 3.2.3 and measured sarcomere 
length and Ca2+ transients were measured using the IonOptix system. Then, to 
determine if Ca2+ release or reuptake was impaired in the CKO CMs, I stimulated the 
CMs with the β-adrenergic stimulator, isoproterenol. Finally, I assessed the relative SR 
content using the ryanodine receptor stimulator, caffeine.  
 
3.1.3 Rationale for measuring contraction and Ca2+ transients using Fura-2-AM and 
the IonOptix system  
The IonOptix system is ideal and well suited for studying contraction and Ca2+ 
transients due to its video edge detector and IonWizard Core Analysis Software as well 
as its dual-excitation fluorescence photomultiplier system. This is especially ideal for 
measuring Ca2+ transients with the fluorescent Ca2+ indicator, Fura-2 
pentacetoxymethyl AM ester (Fura-2-AM, Molecular Probes). Fura-2 is advantageous 
as the endogenous esterase enzymes inside the cell cleave the AM groups attached to 
fura-2 leaving it free to bind intracellular Ca2+.  The Ca2+ bound by Fura-2 can then be 
measured by the dual-excitation photomultiplier system that detects fluorescence at an 
emission of 510 nm. In the presence of intracellular Ca2+, fura-2 is excited at 340 nm 
and in its absence; it is excited at 380 nm [129, 130]. The ratio of fluorescence at 
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340/380 allows for the determination of the relative concentration of free intracellular 
Ca2+.  
 	  
3.1.4. Rationale for using isoproterenol and ryanodine 
 Isoproterenol is known to stimulate β-adrenergic receptors, which in turn activate 
PKA. PKA and CAMKII are the two major proteins responsible for phosphorylating the 
ryanodine receptor. I hypothesized that the mTOR-KO CMs may exhibit dysfunction in 
one or more components involved in EC-Coupling. Consequently, I challenged the CKO 
CMs using isoproterenol. Several groups use isoproterenol to induce what is termed 
spontaneous Ca2+ waves (SCW) or Ca2+ sparks [131, 132]. I treated control and CKO 
CMs with isoproterenol to evaluate any differences between those two groups. 
Simultaneously, I also used the ryanodine receptor inhibitor, ryanodine to assess if that 
decreased the amount of SCWs [69].   
 
3.1.5. Rationale for using caffeine  
 Caffeine is a well-known stimulator for Ca2+-induced Ca2+ release (CICR) from 
RYRs on the SR. It has become a useful tool to determine the Ca2+ content of 
intracellular membrane storage organelles such as the SR of intact cardiac muscle cells 
[133, 134]. It is an advantageous pharmacological tool because it has a dual 
mechanism of action depending on what concentration of caffeine is given. At low 
concentrations (< 1 mM), activation of RYR occurs mainly from the sensitivity of the 
channel to cytosolic Ca2+. However, high concentrations such as the 10 mM 
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concentration I used in this study, increase the sensitivity of the ryanodine receptor to 
luminal Ca2+ [135].  
 
3.2. Methods 
3.2.1. Subcellular fractionation of whole heart tissue.  
Subcellular fractionation was carried out as specified in section 2.2.16.  
 
3.2.2. Western Blot analysis 
 After the fractionation protocol described in the above section (3.2.1), I performed 
immunoblotting exactly the same way as described in section 2.2.4.  I used the following 
primary antibodies: phospho serine 2808-RYR (Badrilla), RYR (Thermo Scientific), 
SERCA2a (Santa Cruz), IP3R (Millipore), VDAC (Cell Signaling), GAPDH (Santa Cruz), 
p-PLN (Cell Signaling), and PLN (Cell Signaling).   
 
3.2.3. Isolation of adult murine ventricular myocytes for Ionoptix 
CMs from CKO and CON mice were isolated as described in section 2.2.5. CMs 
were re-loaded with Ca2+ using increasing concentrations of Ca2+ (0.06 mM, 0.24 mM, 
0.6 mM, 1.2 mM) for 10 minutes each before using them for Ca2+ transients and 
contraction measurements.  
 
3.2.4. Measurement of Ca2+ transients and sarcomere length shortening 
Myocytes were loaded with Ca2+ indicator Fura 2-AM (5 µM) for 15 minutes at 
25°C. Myocytes attached to a coverslip were placed in a chamber mounted on the stage 
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of an inverted microscope (Nikon Eclipse, Figure 3.1) and superfused at approximately 
2 mL/min at 37°C with a buffer containing 10 mM glucose, 137 mM NaCl, 5.4 mM KCl, 
0.5 mM MgCl2, 10 mM HEPES (pH = 7.4), and 1.2 mM CaCl2. The cells were field-
stimulated at a frequency of 2 Hz. A video-based edge detector was used to capture 
and convert changes in cell length during shortening and re-lengthening into an analog 
voltage signal. Cell contractions were assessed using the following indicators: peak 
shortening, time to 90% PS (TPS), time to 90% re-lengthening (TR90) and maximal 
velocities or shortening and re-lengthening (± dL/dt) (Figure 3.2A). Ca2+ was evaluated 
by examining the Fura-2 emission ratio of intracellular to extracellular Ca2+ as previously 
described [136](Figure 3.2B).    
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Figure 3.1. Picture of our IonOptix system including the inverted microscope used in 
these experiments. 
 
 
 
 
	  63	  
 
Figure 3.2. Measurements of cardiac function by IonOptix.  
Diagram of measurements used to evaluate cardiac function using the IonOptix system. A) 
Measurements of sarcomere length shortening. TPS (time to peak shortening), TR90 (time to 
90% relaxation), ± dL/dt (departure and return velocity) B) Measurement of Ca2+ transients 
using the ratio of intracellular and extracellular Ca2+.  	  	  
3.2.5. Isoproterenol challenge of isolated adult murine ventricular myocytes and 
ryanodine treatment 
CMs were inoculated with or without 1 µM ryanodine prior to pacing. The cells 
were then perfused with the buffer containing the components listed in section 3.2.3 and 
1 µM isoproterenol. CMs were stimulated at 0.5 Hz for 5 minutes to allow equilibration to 
the isoproterenol and the stimulation. Increased pacing rates (0.5, 1.0, and 2.0 Hz) were 
used to field-stimulate CMs for one minute to induce spontaneous Ca2+ waves (SCW). 
Pacing was stopped at each frequency for 10 seconds to determine delayed after 
depolarizations (DADs). The scheme for the isoproterenol experiment is displayed 
below (Figure 3.3).    
	  64	  
Figure 3.3. Scheme of isoproterenol treatment and subsequent pacing protocol using the 
IonOptix system.  
 
 
3.2.6. Caffeine stimulation in isolated adult murine ventricular CMs 
CMs were field stimulated at 0.5 Hz to steady state for 1 minute before pacing 
was stopped for 30 seconds and 10 mmol/L caffeine was rapidly applied. The caffeine 
was allowed to washout for another 30 seconds and the CMs were paced again at 0.5 
Hz to re-attain the same steady state [137]. 
 
3.2.7. Calculation of %spontaneous calcium waves (%SCW)  
 The number of Ca2+ peaks in a one-minute time period was counted for each 
pacing frequency to determine the regular amount of peaks in each pacing frequency. 
The spontaneous, extra Ca2+ peaks were counted and compared to the number of 
regular peaks to determine the % spontaneous Ca2+ waves. To calculate the DADs I 
counted the number of peaks after pacing was stopped for that 10-second period.    
 
 
 
	  65	  
3.2.8. Statistical analysis 
 Results were analyzed using Graph Pad’s PRISM software. Statistical tests were 
applied according to the experimental design as indicated in the figure legends. For 
comparisons of two groups, a student t-test was applied. For comparison of multiple 
groups, one-way ANOVA was used. Tukey’s post hoc test was used as a post-test for 
one-way ANOVA. P values are also shown in the figures or graphs. All results are 
reported as means ± SEM.  
 
3.3. Results 
3.3.1. mTOR is localized in both cytosolic and subcellular fractions 
 To confirm the localization of mTOR to the SR/mitochondria, I used the 
subcellular fractionation method described in section 3.2.1 and obtained a cytosolic and 
an SR/mito fraction for both control and CKO hearts. Western blot analysis revealed 
mTOR was located in both the cytosolic and SR/Mito fractions as shown (Figure 3.4). 
SERCA expression levels were unchanged in both the cytosolic and SR/mitochondria 
fractions. GAPDH and VDAC were used as loading controls and to verify the purity of 
the fractions. 
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Figure 3.4. mTOR is localized in both cytosolic and subcellular fractions 
A) Representative immunoblot of hearts prepared using an ultracentrifuge to obtain subcellular 
fractions. mTOR was present in both the cytosolic and SR/mitochondria fractions. B) 
Quantification of the amount of mTOR in the cytosol (left) and the SR/mitochondria fractions 
(right). GAPDH was used as a loading control for the cytosolic fraction while VDAC was used as 
the control for the SR/Mito fraction. N=4 for all groups. p-values are listed on graphs. 
 
3.3.2. CMs isolated from mTOR-CKO mice have decreased contractility and a smaller 
calcium transient ratio.  
 After confirming the localization of mTOR to the SR/mitochondria fractions, I 
evaluated CM contraction and Ca2+ transients at baseline. To do this, CMs were 
isolated using the method described in section 3.2.1 and examined for contractility and 
Ca2+ transients using the method in 3.2.2. Using this system, I observed that CKO CMs 
have both weaker and slower contractions as well as a decreased Ca2+ transient ratio 
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(Figure 3.5A). Supporting this observation, quantifiable parameters of contractility and 
Ca2+ transients of CMs isolated from CKO and control mice also exhibited significant 
differences from each other. Peak shortening was significantly decreased in CKO CMs 
compared to controls while time to 90% peak shortening (TPS), and time to 90% re-
lengthening (TR90) were significantly increased compared to controls (Figure 3.5B). 
Ca2+ transient ratio was also quantifiably decreased in the CKO CMs versus controls 
(Figure 3.4B). These data indicate CKO CMs have significantly worse contractile 
function and weaker Ca2+ transients at baseline compared to controls.  
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Figure 3.5. Cardiomyocytes isolated from mTOR-KO mice have weaker contractility and a 
smaller calcium transient ratio. 
A) Representative traces of sarcomere length contraction and Ca2+ transients in control and 
mTOR-KO CMs. CKO CMs had both weaker and slower contractions as well as a lower Ca2+ 
transient ratio. B) Time to peak shortening and time to 90% relaxation were both significantly 
increased in CKO CMs. Peak shortening was significantly lower in CKO CMs compared to 
controls and Ca2+ transient ratio was also significantly decreased in CKO CMs. N=3 
independent experiments, 8-12 cells total for both groups. p-values are all displayed on graphs.    
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3.3.3. Isoproterenol challenge of CKO cardiomyocytes did not show an increase in the 
percent of spontaneous Ca2+ waves and ryanodine inhibition of the ryanodine receptor 
did not decrease the amount of spontaneous Ca2+ waves.  
 Due to the decreased Ca2+ transient ratio and weaker contractions of the CKO 
CMs, I hypothesized mTOR may play an important role in EC-coupling. To test this 
hypothesis, I challenged the CKOs with 1 µM isoproterenol and ± 1 µM ryanodine at 
increasing pacing rates from 0.5 Hz to 4.0 Hz. Isoproterenol is a known beta-adrenergic 
receptor stimulator that activates PKA. PKA is known to phosphorylate the ryanodine 
receptor and result in increased release of Ca2+ from the SR. Isoproterenol can also 
trigger spontaneous Ca2+ waves (SCWs) and delayed after depolarizations (DADs) that 
are indicative of premature spontaneous Ca2+ release during diastole [138]. Based on 
the initial baseline IonOptix data, I hypothesized that mTOR-CKO CMs had a defect 
either in Ca2+ release or reuptake. If there was dysfunction in Ca2+ release, I expected 
the CKO CMs to possibly have increased SCW or DADs upon isoproterenol stimulation 
relative to controls. However, there was no difference between the CKO and control 
CMs and the percentage of SCW. In addition, ryanodine treatment did not decrease the 
amount of SCWs (Figure 3.6). Therefore, hyper-phosphorylation of the ryanodine 
receptor is not the cause of the weaker contractions and smaller Ca2+ transients.  
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Figure 3.6. mTOR-KO CMs do not have significantly more %SCW than controls and 
ryanodine did not significantly decrease the percentage of SCWs.  
Quantification of the number of SCW compared to the number of normal Ca2+ peaks to 
determine %SCW with and without ryanodine treatment. There was no difference in the %SCW 
between CKOs and controls with or without treatment. N = 7 (CON), 7(CKO), 9 (CON + 
ryanodine), 11 (CKO + ryanodine).  
 
3.3.4. ,mTOR-CKO CMs do not show a change in any major EC-Coupling protein.  
 I next confirmed the isoproterenol data and determined that there was no change 
in ryanodine receptor phosphorylation. I isolated adult CMs from controls and CKO mice 
and performed the same fractionation protocol as figure 3.4. I blotted for phospho-
ryanodine receptor (p-RYR) and total RYR. I found no significant difference in the ratio 
of p-RYR:RYR in CKO CMs versus controls (Figure 3.7) in either the cytosolic or 
SR/mitochondria fractions. There was also not find any significant difference in p-PLN or 
SERCA expression.     
	  71	  
 
Figure 3.7. CKO hearts do not show a change in any major EC-Coupling protein.  
A) Representative immunoblot from control and CKO hearts that underwent ultracentrifugation 
to obtain subcellular fractions. Analysis of the blots showed there was no increase in p-RYR in 
the CKO hearts. There was also no change in SERCA and p-PLN. VDAC was used as a loading 
control for the SR/mito fraction while GAPDH was used as the loading control for the cytosolic 
fraction. B) Quantification of the amount of p-RYR, p-PLN, and SERCA in controls and CKO 
hearts. N = 6 for all groups.  
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3.3.5. Caffeine stimulation of control and CKO cardiomyocytes showed CKO CMs have 
decreased relative SR Ca2+ content   
 I hypothesized that the knockout of mTOR may lead to decreased SR content 
and slower release and reuptake of Ca2+. To test this hypothesis, I challenged CMs 
isolated from CKO and control mice with 10 mmol/L caffeine using the method 
explained in section 3.2.6. CKO CMs exhibited significantly reduced caffeine- induced 
Ca2+ transients and significantly smaller peak shortening as shown by the 
representative images and quantitative data (Figure 3.8). The majority of the control 
CMs had sharp peaks in response to caffeine as demonstrated by the representative 
image. On the other hand, the CKO CMs were not as responsive to the caffeine. They 
had wider peaks and sometimes multiple peaks as shown in the representative images 
(Figure 3.8A). Quantification of these peaks confirmed these observations. Peak 
shortening (% cell length) and Ca2+ transient ratio were both significantly smaller in 
CKO CMs (Figure 3.7B).  These two indicators showed that mTOR-KO CMs had a 
significantly diminished response to caffeine. The smaller Ca2+ transient induced by 
caffeine in the CKO CMs also demonstrates that the relative SR Ca2+ content is 
significantly smaller than in control CMs.  
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Figure 3.8. mTOR-CKO CMs have lower relative SR calcium content than controls.  
A) Representative images from caffeine experiments. Top. Representative tracing of sarcomere 
length from CON and CKO CMs stimulated with caffeine. CKO peaks were smaller and 
sometimes had multiple contractions. Middle. Representative tracing of Ca2+ transients from 
CON and CKO CMs stimulated with caffeine. The CKO CM Ca2+ transient ratio was significantly 
lower than controls. Bottom. Quantification of the peaks resulting from caffeine stimulation. CKO 
CMs had significantly smaller % peak shortening and Ca2 transients than controls indicating the 
CKO CMs have a lower SR Ca2+ content. N = 12 cells from 3 (CON) and 4 (CKO) mice. P-
values are displayed on graphs as determined by student’s t-test.  
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3.4. Discussion 
3.4.1. Summary and interpretation of results 
 I hypothesized that mTOR may play an important role in Ca2+ signaling in CMs 
based on other studies supporting a role for mTOR in Ca2+ signaling in non-muscle cell 
types and my own data showing mTOR was localized to both the cytosol and the 
SR/mitochondria. To demonstrate a functional role for mTOR in Ca2+ signaling, I 
isolated CMs from control and CKO mice and tested their baseline CM contraction/Ca2+ 
transients using our IonOptix system. The CMs isolated from CKO mice displayed 
significantly weaker contractions and had reduced Ca2+ transients (Figure 3.5). This 
was expected based on the in vivo data which showed that mTOR was necessary for 
cardioprotection against I/R injury. Therefore, I also expected CMs isolated from CKO 
mice to have worse baseline function, despite the ex vivo data showing that the CKO 
hearts recovered better in an ex vivo Langendorff model.  
 Based on the baseline IonOptix data, I hypothesized that the CKO CMs had 
either dysfunctional Ca2+ release or reuptake, possibly due to a change in one or more 
proteins involved in EC-Coupling. To test if Ca2+ release was impaired, I stimulated the 
CMs with the β-adrenergic agonist, isoproterenol, resulting in increased release of Ca2+ 
from the SR through RYRs. I also treated some of the cells with the RYR inhibitor, 
ryanodine. I speculated if RYRs were hyper-phosphorylated then inhibition of RYRs with 
ryanodine would decrease the amount of Ca2+ sparks. I found that CKO CMs did not 
have significantly more SCWs than control CMs (Figure 3.6). Most likely this means the 
weaker contractions and smaller Ca2+ transients are not due to the hyper-
phosphorylation of RYRs. This is reinforced by the Western blot data showing there was 
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no significant increase in the phosphorylation of RYRs between control and CKO CMs 
(Figure 3.7). Therefore, the cause of the weaker contractions and smaller Ca2+ 
transients is due to another mechanism.  
 Since I determined that changes in the RYR receptor does not explain the 
differences in CKO CMs, I decided to evaluate the SR Ca2+ content in the CKO CMs 
versus control CMs. To determine the relative SR Ca2+ content, I stimulated the CMs 
with caffeine, which activates Ca2+-induced Ca2+ release on the SR. I found significant 
differences in the relative SR Ca2+ content between the CKO CMs and the control CMs. 
CKO CMs had significantly less SR Ca2+ as demonstrated by their smaller Ca2+ 
transient ratio (Figure 3.8). A smaller amount of SR Ca2+ could then explain the baseline 
IonOptix data. Decreased expression of the IP3R as shown in Figure 2.17 could 
potentially be the cause. Reduced IP3R levels could destabilize MAMs resulting in 
increased mitochondrial Ca2+ uptake. This could result in less Ca2+ being taken up by 
SERCA into the SR as more Ca2+ than usual is in the mitochondria.  
 I did not investigate the Ca2+ reuptake in the CKO CMs, however, I did not find 
any evidence to investigate Ca2+ reuptake based on western blot data that exhibited no 
changes in SERCA expression or increase in phospho-phospholamban (p-PLN, Figure 
3.7). Therefore, I concluded that SERCA down-regulation and/or an increase in p-PLN 
was likely not the cause of lower Ca2+ in the SR or the weaker contractions and Ca2+ 
transients I observed at baseline. The mechanism has yet to be determined though it 
may be through a reduction of IP3R expression. 
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Chapter Four 
 
 
THE ROLE OF MTOR IN OTHER PATHOLOGICAL 
SETTINGS ESPECIALLY DIABETES MELLITUS 
 
4.1. Introduction 
4.1.1. Specific Aim 3: To define the role of cardiac mTOR in metabolic disorders 
such as diabetes mellitus (DM). 
 mTOR is an important contributor to several cellular functions and has a major 
role in cellular and glucose metabolism. Therefore, I studied its role in other pathological 
settings, especially the metabolic syndrome and DM. Indeed, patients with DM is 
associated with a two-fold higher risk of developing heart failure in men and a four to 
five-fold greater risk in women compared to healthy controls and accounts for 66% of 
the mortality in the first year post MI [139-141]. Even more concerning is that, despite 
the advanced therapeutics available, the rate of HF in patients with diabetes has 
increased over time [142]. Consequently, there is a need to thoroughly investigate key 
proteins in metabolism and cardiovascular disease such as mTOR in further detail in 
order to develop new therapeutic targets in DM patients.  
 Our previous study demonstrated that overexpression of mTOR was 
cardioprotective in a mouse model of obesity. Glucose tolerance and insulin resistance 
were comparable between mTOR-Tg and WT mice, however, functional recovery after 
I/R using the ex vivo Langendorff perfusion model was significantly better in mTOR-Tg 
mice on a HFD than WT mice on a HFD [8]. Overall, this study demonstrated mTOR 
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was significantly better for cardioprotection in a mouse model of obesity. My next 
objective was to verify if mTOR was an important factor involved in cardioprotection in a 
mouse model of obesity. As a preliminary study, I placed the control and CKO mice on a 
HFD for 12 weeks. Following, I evaluated these mice for hyperglycemia and obesity 
before subjecting their hearts to I/R injury using the Langendorff perfusion model.  
 
4.1.2. Rationale for using a diet-induced obesity mouse model 
 C57BL6/J mice on a HFD display the three key risk factors of metabolic 
syndrome: obesity, glucose intolerance, and insulin tolerance [8, 143, 144]. These risk 
factors are major determinants for developing diabetes and/or MI. Genetic mouse 
models such as db/db mice are not as relevant to human obesity since they are caused 
by a mutation in one gene whereas human obesity is most likely mediated by multiple 
factors including diet, lifestyle, and genetics. Polygenic mouse models of obesity such 
as the New Zealand Obese (NZO) mice are available, however, a diet-induced model 
most closely resembles the metabolic state in humans.  
 
4.2. Methods 
4.2.1. Tamoxifen administration (injections) 
 At 6 weeks of age, CKO and control mice were administered a series of five 
tamoxifen injections over a period of one week. Thirty mg/kg/d of tamoxifen were 
dissolved in corn oil and given to the mice via intraperitoneal (IP) injections.  
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4.2.2. High-fat diet administration. 
 At 6-8 weeks of age, CKO and control mice were given either a normal chow diet 
(NCD) consisting of 24.7% energy from protein, 13.2% from fat, and 62.1% from 
carbohydrates (5053, PicoLab, St. Louis, MO) or a HFD consisting of 14.9% energy 
from protein, 26.0% carbohydrate, and 59.0% fat (S3282, 549.0 kcal/100 g, Bio-Serv, 
Frenchtown, NJ) for 12 weeks.  
 
4.2.3. Collection of blood glucose levels. 
 At the end of 12 weeks, mice were fasted overnight and blood samples were 
drawn from the tail vein and measured using a commercially available glucose meter 
(OneTouch Ultra blood glucose meter, LifeScan, Milpitas, CA).  
 
 
4.2.4. Statistical analysis 
 Results were analyzed using Graph Pad’s PRISM software. Statistical tests were 
applied according to the experimental design as indicated in the figure legends. For 
comparisons of two groups, a student t-test was applied. For comparison of multiple 
groups, one-way ANOVA was used. Tukey’s post hoc test was used as a post-test for 
one-way ANOVA. P values are also shown in the figures or graphs. All results are 
reported as means ± SEM.  
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4.3. Results 
 
4.3.1. Mice on a HFD exhibit large body weights and high blood glucose levels relative 
to mice on a NCD. 
 After 12 weeks on HFD, control and CKO mice on a NCD and HFD were 
weighed. A blood glucose test was performed to determine if the mice were exhibiting 
hyperglycemia. As this was a preliminary study, these mice were not evaluated for 
glucose tolerance and insulin resistance. Body weight and blood glucose levels were 
found to be significantly higher in control mice on the HFD versus controls on a NCD. 
Body weight and blood glucose levels for the CKO mice were not significantly higher 
though they were trending that way (Table 5 and Figure 4.1). Most likely, the lack of 
significance was due to the low sample number for these mice as power analysis 
indicated I would need a sample size of 8 per group based on a power of 0.80 and a 
type 1 error rate of 0.05. Likewise, there were no significant differences in body weight 
and blood glucose levels between CON and CKO mice on a HFD or on a NCD (Table 5 
and Figure 4.1)   
 
Table 5. Comparison of body weight, heart weight, and HW:TB between control and CKO 
mice on a NCD and a HFD 
 CON NCD CKO NCD CON HFD CKO HFD 
Body Weight 31.12 ± 1.37 g 31.43 ± 0.55 g 42.60 ± 3.08 g 40.40 ± 5.57 g 
Heart Weight 0.19 ± 0.009 g 0.19 ± 0.019 g 0.21 ± 0.019 g 0.21 ± 0.030 
HW:TB 0.0083 ± 0.0004 0.0083 ± 0.0008 0.0093 ± 0.0009 0.0092 ± 0.001 
Values shown are means ± SEM. N = 7(CON NCD), 4 (CKO NCD), 6 (CON HFD), and 4(CKO 
HFD) 
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Figure 4.1. Body weight and fasting blood glucose levels are significantly higher in 
control mice on a HFD.  
Bar graph showing control mice on a HFD had significantly increased body weight compared to 
controls on a NCD. B) Bar graph demonstrating CON mice on a HFD have significantly 
increased fasting blood glucose levels. N = 7 (CON NCD), 4 (CKO NCD), 6 (CON HFD), and 4 
(CKO HFD). P-values displayed on graph.    
 
 
 
4.3.2. CKO mice hearts recover significantly better than CON on both a NCD and a 
HFD.  
 To determine if mTOR is necessary to protect the heart against I/R injury in a 
mouse model of obesity, I next placed CKO and control mice on a HFD for 12 weeks 
and then evaluated their cardiac function via ex vivo Langendorff. I found that CKO mice 
recovered better then their littermate controls on both a NCD and HFD (Figure 4.4). 
There was also no significant difference between the recoveries of the control mice on a 
HFD versus a NCD and likewise between CKO mice on a HFD versus a NCD. Most 
likely this was due to the low sample number. A larger number may have revealed 
differences between these groups as power analysis indicated I would need 8 mice per 
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group given a power of 0.80 and a type 1 error rate of 0.05 to reliably detect a 2-fold 
difference in %LVDP recovery. 
 
Figure 4.2. mTOR-CKO mice on a NCD and HFD recover better after I/R injury in the ex 
vivo Langendorff model.  
A) Representative tracings showing the entire Langendorff experiment. B) Quantitation of the 
LVDP at baseline and every 10 minutes of reperfusion. mTOR-KO mice on a NCD and a HFD 
recovered significantly better than control mice on a NCD and HFD. C) %LVDP recovery of 
control and CKO mice on both a NCD and HFD. N = 7 (CON NCD), 4 (CKO NCD), 6 (CON 
HFD), and 4 (CKO HFD). P-values are listed on the graphs as determined by one-way ANOVA 
and Tukey’s post hoc test.   
 
4.4. Discussion 
4.4.1. Summary and interpretation of results 
 Since mTOR is highly involved in glucose metabolism and fatty acid oxidation, I 
decided to investigate the role of mTOR in the metabolic syndrome and DM. As a 
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preliminary study, I placed mTOR-KO mice on a HFD along with their littermate controls 
for 12 weeks and then assessed them for their body weight and their blood glucose 
levels. I found significant changes to the body weight and blood glucose levels in the 
controls that were on a HFD but not in the CKOs. Most likely this was due to the low 
sample number of the CKO mice and if repeated in the future, the body weight and 
blood glucose levels would be significantly higher.  
As part of the preliminary study, I subjected the mice to global ischemia-
reperfusion injury using ex vivo Langendorff. The CKO hearts again recovered better 
than control hearts on both a NCD and a HFD. This was surprising as I expected the 
HFD to be especially detrimental to the mTOR-CKO hearts. The better recovery of the 
CKO hearts on a HFD in the ex vivo system may again be explained by the lack of 
insulin stimulation and lower amount of Ca2+ in the SR. Since there is less Ca2+ in the 
SR, there is less Ca2+ entering the CM during ischemia and therefore, the CKO hearts 
are recovering better. If insulin were given at the start of reperfusion, most likely this 
would result in a lower recovery for mTOR-CKO hearts on a HFD.  
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Chapter Five 
 
 
Concluding Remarks 
 
 
5.1. Summary and discussion of results 
  In our previous studies, overexpression of mTOR was shown to be 
cardioprotective against a number of different pathological stimuli including I/R injury, 
TAC-induced hypertrophy, and I/R injury in a mouse model of obesity [2, 7, 8]. These 
studies clearly established that mTOR overexpression significantly protected the heart 
against negative stimuli and suggested the mTOR signaling pathway was a potential 
therapeutic target. However, we did not establish the role of mTOR in cardioprotection 
and other pathological settings. Therefore, in order to demonstrate mTOR prevented 
cell death and left ventricular remodeling, I established a tamoxifen-inducible, CM 
specific mTOR-KO mouse line and studied it in a number of different functional settings. 
I hypothesized loss of mTOR would be detrimental to the heart in the I/R injury model. 
As expected, the mTOR-KO mice had reduced cardiac function and increased fibrosis 
just seven days after in vivo I/R surgery (Figure 1.4). Since our previous studies 
demonstrated a beneficial effect of mTOR in both in vivo and ex vivo I/R injury, I 
anticipated the CKO hearts would conversely have a lower %LVDP recovery than their 
littermate controls. However, upon subjecting these hearts to the Langendorff protocol, I 
found a very surprising and yet very consistent result. The mTOR-KO mice recovered 
significantly better than their littermate controls (Figure 2.8).  
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 As a result of this unexpected finding, I explored the role of mTOR in cardiac 
physiology and EC-coupling rather than focus on cell death. I hypothesized that one of 
the proteins involved in CM contraction may be altered in the mTOR-CKO hearts, 
resulting in lower overall SR Ca2+ content. The lower SR Ca2+ and subsequent loss of 
external stimuli normally present in vivo was causing the mTOR-KO hearts recovered 
better after I/R injury. I tested a number of different stimuli that triggered various 
components of the EC-coupling pathway. First, I examined ones that increased Ca2+ 
release through ryanodine receptors such as isoproterenol and pacing. None of these 
significantly decreased the recovery of the mTOR-KO hearts (Figures 2.11 and 2.13). 
This implies the hyper-phosphorylation of the ryanodine receptor is not the cause of my 
hypothesized lower amount of Ca2+ in the SR. This was later further confirmed by 
western blot analysis (Figure 3.6).  
 Then, since mTOR is a part of the insulin-signaling pathway, I tested direct 
insulin stimulation. Insulin may be one of the missing external factors that are present in 
vivo that the Langendorff system lacks. I found that insulin given at reperfusion 
significantly decreased the recovery of the CKO hearts. One potential mechanism for 
insulin blunting the recovery of the CKO mice is that insulin signaling activates Ca2+ 
release from the IP3R and leads to increased mitochondrial uptake of Ca2+ [121, 122]. 
mTOR is known to associate with MAMs which requires IP3R to have MAM integrity. In 
MEFs that had mTORC2 knocked down, expression of the IP3R3 was found to be 
significantly decreased [5]. Taken together, these results show mTOR is an important 
contributor for cardioprotection against I/R injury although the mechanism is unclear as 
to why the CKO hearts recover better without insulin. 
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 For the second aim, since the ex vivo data was unclear due to missing elements 
normally present in vivo, I utilized isolated CMs as our knockout is in specifically CMs to 
determine if mTOR helped maintain normal Ca2+ transients and contraction. To analyze 
changes in Ca2+ transients and contractility in mTOR-CKO CMs, I isolated CMs and 
studied their contraction and Ca2+ transients using our IonOptix system. I found that 
CMs isolated from mTOR-CKO mice had significantly weaker contractions and smaller 
Ca2+ transients (Figure 3.4). Consistent with my ex vivo data, isoproterenol stimulation 
did not result in significantly more spontaneous contractions between the CKO and 
control CMs (Figure 3.5). If RYR2 was hyper-phosphorylated in CKO CMs, 
isoproterenol stimulation should have resulted in increased SCWs.  However, 
stimulation with caffeine did demonstrate there was significantly lower relative SR Ca2+ 
in CKO CMs compared with controls, although the mechanism for why there is lower SR 
Ca2+ in these CMs also remains unclear. It is possible that the lower SR Ca2+ and the 
better recovery of the CKO hearts in the ex vivo Langendorff system is tied to the same 
mechanism. This is potentially due to downregulated IP3R levels, resulting in more Ca2+ 
being taken up by the mitochondria leaving less Ca2+ to be taken up into the SR by 
SERCA.  
 Finally for my third aim, as a preliminary study, I investigated the role of mTOR in 
a mouse model of obesity by placing CKO mice and their littermate controls on a HFD 
for 12 weeks, since our previous study demonstrated the sufficiency for mTOR to guard 
against harmful cardiovascular effects in the metabolic syndrome [8]. The result was 
unexpected when I subjected these hearts to global ischemia. Once again, the hearts 
from the CKO mice recovered better then their littermate controls (Figure 4.2). This 
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unforeseen result could be due to missing insulin and or other external factors. It is 
probable that insulin stimulation of the CKO mice on a HFD would significantly blunt 
their recovery. Notably, the HFD CKO hearts recovered better than control hearts on a 
NCD.   
 
5.2. Conclusion 
This dissertation focused primarily on the role of mTOR in cardiac function, a role 
that has not yet been well defined in I/R injury and diabetes mellitus. This study is 
unique in that both mTORC1 and mTORC2 were knocked out. Most of the other studies 
involving mTOR have focused on either inhibiting mTORC1 through a RAPTOR 
knockout or by using rapamycin or its derivatives. Some studies also inhibited the 
expression of mTORC2 through a RICTOR knockout. However, these studies only 
focus on one of the mTOR complexes. Since mTOR expression is significantly up 
regulated in heart failure patients, we used a model that over-expressed mTOR [7]. 
However, it was unknown as to whether this was a compensatory or a de-compensatory 
response until our study demonstrated mTOR prevented cell death and helped maintain 
normal cardiac function in both in vivo and ex vivo models of I/R injury [2]. 
Since our previous report in CMs focused on the beneficial effects of mTOR 
over-expression, I determined the consequences of a CM-specific mTOR knockout. My 
studies in this dissertation clearly demonstrate loss of mTOR is detrimental to the heart 
in various functional pathological conditions although insulin is also required in ex vivo 
I/R injury. I also established mTOR was required to maintain normal contractions and 
Ca2+ transients in vitro using our IonOptix system, and that mTOR CKO CMs had lower 
relative SR Ca2+ content. However, I could not identify the mechanism responsible for 
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these different findings although insulin and the IP3R2 may play a key role in the overall 
mechanism since IP3R expression was significantly lowered in the SR/mito fractions of 
the CKO hearts. Based on my data and the literature, I hypothesized that loss of mTOR 
may lead to the following (See Figure 5.1): 1) decreased IP3R expression (Figure 2.17) 
and possible loss of MAM integrity. 2) This leads to possible increased mitochondrial 
Ca2+ uptake and significantly lowered SR Ca2+ (Figure 3.8). Lower SR Ca2+ then results 
in 3) decreased Ca2+ transients and weaker contractions (Figure 3.5). Without insulin 
stimulation, increasing release of Ca2+ from release channels, CKO hearts can recover 
better because there is less Ca2+ entering the mitochondria. However, with insulin, there 
may be increased Ca2+ release combined with possible altered MAM integrity and 
amplified mitochondrial Ca2+ uptake leading to the decreased recovery of the CKO 
hearts, although this is mere speculation.   
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Figure 5.1. Scheme of our speculated mechanism for the findings in this dissertation.  
Illustration of my findings and speculated mechanism. Numbers correspond to the numbers 
written above in the text in section 5.2. 1) I found that loss of mTOR may lead to reduced 
expression of the IP3R (Figure 2.17). This could cause more Ca2+ to be taken up by the 
mitochondria, although not enough to trigger cell death. The lower amount of Ca2+ in the cytosol 
then leads to 2) reduced Ca2+ reuptake and SR Ca2+ content (Figure 3.8). This then results in 3) 
decreased Ca2+ transients and weaker contractions (Figure 3.5).  
 
 
5.3. Limitations and future directions 
 The research described in this dissertation was primarily focused on 
characterizing our cardiac specific mTOR-KO mice and the role of mTOR in functional 
cardiovascular studies and consequently, has some limitations. Although it established 
clear and key differences between the CKO mice and their littermate controls and 
demonstrated mTOR was required for shielding the heart against adverse conditions 
when given insulin, it did not specifically look at whether cell death was prevented in 
both the ex vivo and in vitro studies. Therefore, there must be consideration that mTOR 
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is only partially essential for cardioprotection. Future studies are necessary to determine 
the necessity of mTOR in the two major forms of cell death: apoptosis and necrosis.  
Another major limitation of these studies is the lack of mechanism for the findings 
I discovered in these experiments. I saw a decrease in IP3R expression but I did not 
look in-depth to determine if IP3R reduction was the cause of my findings. More 
thorough experimentation is needed to determine the mechanism. However, I did show 
a new finding in location of mTOR which is located within the SR/mitochondria and 
established loss of mTOR was necessary to maintain normal Ca2+ transients and 
contraction. Although a clear mechanism was not found, there is the potential for new 
findings based on my discoveries in this dissertation concerning a role for mTOR in 
SR/mito signaling. Having a clear mechanism would then allow for further studies 
involving mTOR and could provide new insights into potential therapeutics for different 
forms of heart disease such as MI, HF, and DM.  
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